<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nutr Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Nutr Sci</journal-id><journal-id journal-id-type="publisher-id">JNS</journal-id><journal-title-group><journal-title>Journal of Nutritional Science</journal-title></journal-title-group><issn pub-type="epub">2048-6790</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25191546</article-id><article-id pub-id-type="pmc">4153080</article-id><article-id pub-id-type="doi">10.1017/jns.2012.18</article-id><article-id pub-id-type="pii">S2048679012000183</article-id><article-id pub-id-type="publisher-id">00018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Human and Clinical Nutrition</subject></subj-group></article-categories><title-group><article-title>Substitution of TAG oil with diacylglycerol oil in food items improves the
predicted 10 years cardiovascular risk score in healthy, overweight subjects</article-title><alt-title alt-title-type="left-running">V. H. Telle-Hansen <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">Short diacylglycerol and health
effects</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Telle-Hansen</surname><given-names>Vibeke H.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Narverud</surname><given-names>Ingunn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Retterst&#x000f8;l</surname><given-names>Kjetil</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wesseltoft-Rao</surname><given-names>Nima</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mosd&#x000f8;l</surname><given-names>Annhild</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Granlund</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Christiansen</surname><given-names>Kirsti Forstr&#x000f8;m</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lamglait</surname><given-names>Amandine</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Halvorsen</surname><given-names>Bente</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Holven</surname><given-names>Kirsten B.</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ulven</surname><given-names>Stine M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Health, Nutrition and
Management</addr-line>, <institution>Faculty of Health Sciences, Oslo and Akershus
University College of Applied Sciences</institution>, <addr-line>Post Box 4, St.
Olavsplass, 0130 Oslo</addr-line>, <country>Norway</country></aff><aff id="aff2"><label>2</label><addr-line>Department of Nutrition</addr-line>,
<institution>Institute for Basic Medical Sciences, University of Oslo</institution>,
<addr-line>Post Box 1046, Blindern, 0317 Oslo</addr-line>, <country>Norway</country></aff><aff id="aff3"><label>3</label><addr-line>Lipid Clinic, Medical Department,
Rikshospitalet</addr-line>, <institution>Oslo University Hospital</institution>,
<addr-line>Post Box 4950, Nydalen, 0424 Oslo</addr-line>, <country>Norway</country></aff><aff id="aff4"><label>4</label><addr-line>Mills DA, Post Box 4644, Sofienberg, 0506
Oslo</addr-line>, <country>Norway</country></aff><aff id="aff5"><label>5</label><institution>Research Institute for Internal Medicine, Faculty
of Medicine, University of Oslo, Rikshospitalet, Oslo University Hospital</institution>,
<addr-line>Post Box 4950, Nydalen, 0424 Oslo</addr-line>, <country>Norway</country></aff><author-notes><corresp id="cor1"><label>*</label><addr-line><bold>Corresponding author:</bold> Kirsten B.
Holven</addr-line>, fax <fax>+47 22851341</fax>, email <email>Kirsten.holven@medisin.uio.no</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2012</year></pub-date><volume>1</volume><elocation-id>e17</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2012</year></date><date date-type="rev-recd"><day>24</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->The online version of this article is published within an Open Access
environment subject to the conditions of the Creative Commons
Attribution-NonCommercial-ShareAlike licence
&#x0003c;<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/2.5/">http://creativecommons.org/licenses/by-nc-sa/2.5/</ext-link>&#x0003e;. The written
permission of Cambridge University Press must be obtained for commercial
re-use.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="S2048679012000183a.pdf"/><abstract abstract-type="normal"><p>Dietary fat is normally in TAG form, but diacylglycerol (DAG) is a natural component of
edible oils. Studies have shown that consumption of DAG results in metabolic
characteristics that are distinct from those of TAG, which may be beneficial in preventing
and managing obesity. The objective of the present study was to investigate if food items
in which part of the TAG oil is replaced with DAG oil combined with high &#x003b1;-linolenic acid
(ALA) content would influence metabolic markers. A 12-week double-blinded randomised
controlled parallel-design study was conducted. The participants (<italic>n</italic> 23)
were healthy, overweight men and women, aged 37&#x02013;67 years, BMI 27&#x02013;35&#x000a0;kg/m<sup>2</sup>, with
waist circumference &#x0003e;94&#x000a0;cm (men) and &#x0003e;88&#x000a0;cm (women). The two groups received
20&#x000a0;g margarine, 11&#x000a0;g mayonnaise and 12&#x000a0;g oil per d, containing either high ALA and
<italic>sn</italic>-1,3-DAG or high ALA and TAG. Substitution of TAG oil with DAG oil in
food items for 12 weeks led to an improvement of the predicted 10 years cardiovascular
risk score in overweight subjects by non-significantly improving markers of health such as
total body fat percentage, trunk fat mass, alanine aminotransferase, systolic blood
pressure, &#x003b3;-glutamyl transferase, alkaline phosphatase and total fat-free mass. This may
suggest that replacing TAG oil with DAG oil in healthy, overweight individuals may have
beneficial metabolic effects.</p></abstract><kwd-group><title>Key words</title><kwd>Diacylglycerol</kwd><kwd>TAG</kwd><kwd>Overweight human subjects</kwd><kwd>Liver markers</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abreviations</title><kwd>ALA, &#x003b1;-linolenic acid</kwd><kwd>ALAT, alanine aminotransferase</kwd><kwd>ALP, alkaline phosphatase</kwd><kwd>ASAT, aspartame aminotransferase</kwd><kwd>CRP, C-reactive protein</kwd><kwd>DAG, diacylglycerol</kwd><kwd>FFM, fat-free mass</kwd><kwd>&#x003b3;-GT, &#x003b3;-glutamyl transferase</kwd><kwd>HOMA-IR, homeostatic model assessment for insulin resistance</kwd><kwd>hsCRP, high-sensitivity CRP</kwd></kwd-group><counts><table-count count="6"/><ref-count count="77"/><page-count count="13"/></counts></article-meta></front><body><p>Prevention and treatment of obesity and obesity-related diseases are major public health
challenges<sup>(</sup><xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref><sup>&#x02013;</sup><xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref><sup>)</sup> and both the total amount of fat and the distribution of fat in the body
are important determinants of the complications associated with obesity<sup>(</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>)</sup>. Surplus energy intake is stored as TAG in adipose tissue either as
subcutaneous or visceral fat. Visceral fat depots, located in the trunk surrounding the
organs, are recognised to be a more active endocrine organ, and contribute to an increased
risk of metabolic complications, than subcutaneous fat depots<sup>(</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>&#x02013;</sup><xref rid="ref7" ref-type="bibr">
<sup>7</sup>
</xref><sup>)</sup>. Hence, the endocrine activity of visceral adipose tissue is an important
factor in the development of the metabolic syndrome<sup>(</sup><xref rid="ref8" ref-type="bibr">
<sup>8</sup>
</xref><sup>)</sup>, and central obesity is more strongly associated with increased risk of
insulin resistance, the metabolic syndrome and CVD than BMI alone<sup>(</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>)</sup>. The endocrine activity of adipose tissue includes secretion of a number
of adipokines (cytokines and hormones) leading to a pro-inflammatory state, and it has been
shown that the reduction of visceral fat effectively prevents cardiovascular
events<sup>(</sup><xref rid="ref10" ref-type="bibr">
<sup>10</sup>
</xref><sup>)</sup>. Also, hepatic accumulation of fat is common in obese individuals and is
associated with hepatic dysfunction<sup>(</sup><xref rid="ref11" ref-type="bibr">
<sup>11</sup>
</xref><sup>)</sup>. Increased adipose tissue, and in particular visceral adipose tissue, is
linked to increased levels of circulating liver function markers, such as alanine
aminotransferase (ALAT) and &#x003b3;-glutamyl transferase (&#x003b3;-GT)<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>&#x02013;</sup><xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref><sup>)</sup>.</p><p>Dietary fat is normally in TAG form, but diacylglycerol (DAG) is a natural component of
various edible oils<sup>(</sup><xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref><sup>)</sup> and is currently used in small quantities in foods as an emulsifier.
Recent studies have shown that high consumption of DAG results in metabolic characteristics
that are distinct from those of TAG, and that these characteristics may be beneficial in
preventing and managing obesity. Experimental studies in human subjects have shown that DAG
(mainly <italic>sn</italic>-1,3-DAG) decreases postprandial TAG compared with TAG
controls<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>,</sup><xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref><sup>)</sup>. Kamphuis <italic>et al.</italic> showed that meals rich in DAG increase
fat oxidation<sup>(</sup><xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref><sup>)</sup>. Dietary DAG has also been shown to reduce body fat (total, subcutaneous,
visceral and hepatic fat mass) compared with TAG<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>)</sup>, and consumption of DAG oil as part of a reduced-energy diet enhances loss
of body weight and fat compared with TAG control oil<sup>(</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>)</sup>.</p><p>Vegetable oils such as flaxseed oil and rapeseed oils are the main dietary sources of the
vegetable <italic>n</italic>-3 fatty acid &#x003b1;-linolenic acid (ALA; 18 : 3). The relation between
intake of ALA and CVD has been studied less extensively than the marine <italic>n</italic>-3
fatty acids and the relation is less clear. Some studies, including clinical trials,
epidemiological investigations and experimental studies, have shown that intake of ALA has
been beneficially associated with CVD risk<sup>(</sup><xref rid="ref23" ref-type="bibr">
<sup>23</sup>
</xref><sup>)</sup> or markers of risk<sup>(</sup><xref rid="ref24" ref-type="bibr">
<sup>24</sup>
</xref><sup>)</sup>. Other studies have found no effect of ALA on CVD risk
markers<sup>(</sup><xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref><sup>&#x02013;</sup><xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref><sup>)</sup>.</p><p>The aim of the present study was to investigate whether intake of food items in which part of
the TAG-based oil has been replaced with DAG combined with high ALA content would influence
metabolic markers such as C-reactive protein (CRP), blood lipids, body composition, liver
function markers and overall cardiovascular risk score in healthy, overweight individuals.</p><sec id="sec1"><title>Experimental methods</title><sec id="sec1-1" sec-type="subjects"><title>Subjects</title><p>Healthy, overweight men and women who were willing to consume margarine, mayonnaise and
oil daily for 14 weeks were recruited via advertisements in local newspapers from October
2008 to February 2009. The inclusion criteria were: age 18&#x02013;70 years, BMI
27&#x02013;40&#x000a0;kg/m<sup>2</sup> and waist circumference &#x0003e;94&#x000a0;cm for men and &#x0003e;88&#x000a0;cm for
women. Exclusion criteria were: type 2 diabetes mellitus, kidney-, liver-, gall bladder-,
coronary-, endocrine- or chronic rheumatic disease, malign cancer during the last 5 years,
hypertension (&#x02265;160/100 mmHg), pregnancy and lactation. Regular use of anti-inflammatory,
lipid lowering and anti-hypertensive medications was not permitted. The present study was
conducted according to the guidelines laid down in the Declaration of Helsinki and all
procedures involving human subjects were approved by the Regional Committee of Medical
Ethics (approval no. 6.2008.1368) and by the Norwegian Social Science Data Services
(approval no. 19667). Written informed consent was obtained from all subjects. The study
was registered at <uri xlink:type="simple" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</uri> (no. NCT01034436).</p></sec><sec id="sec1-2"><title>Study design</title><p>The present study is part of a larger study involving healthy overweight subjects
randomised to three different intervention groups: high ALA-DAG (<italic>n</italic> 10),
high ALA-TAG (<italic>n</italic> 13) and low ALA-TAG (<italic>n</italic> 10) where the aim
of the study was (<xref rid="ref1" ref-type="bibr">1</xref>) to study the effect of
replacing TAG-based food items with DAG-based food items and (<xref rid="ref2" ref-type="bibr">2</xref>) to study the effect of low <italic>v.</italic> high ALA in
TAG-based food items. In the present study, only data relating to the first aim are
presented. In total, ninety-six subjects were screened for eligibility (minimum 4 weeks
prior to the run-in period). For the present aim, forty-nine subjects were randomised and
thirty-nine subjects received allocated interventions. Of the subjects, ten discontinued
the intervention (declined to eat products, hospitalisation, lack of time and no
explanation) and six had to be excluded from the analyses, leaving twenty-three subjects
(<italic>n</italic> 10 and 13) included in the final statistical analyses. A 12-week
double-blinded randomised controlled parallel-design study was conducted at Akershus
University College from February to June 2009. Subjects were allocated to high ALA-DAG or
high ALA-TAG further described in detail later. During a 2-week run-in period prior to the
intervention period, all subjects included the same set of test products. The test
products in the run-in period consisted of sunflower oil-based margarine (20&#x000a0;g) and
mayonnaise (11&#x000a0;g) and sunflower oil (12&#x000a0;g). Fatty acids were given as TAG and the total
amount of ALA in the run-in period was 0&#x000b7;15&#x000a0;g per d.</p><p>At baseline, subjects were randomly assigned and stratified by sex into the intervention
groups receiving products containing either high ALA (8&#x000b7;29&#x000a0;g/d) and
<italic>sn</italic>-1,3-DAG or high ALA (8&#x000b7;51&#x000a0;g/d) and TAG (from now on referred to as the
high-ALA-DAG group and high-ALA-TAG group, respectively) (<xref ref-type="table" rid="tab01">Table 1</xref>). The test products were 20&#x000a0;g margarine, 11&#x000a0;g mayonnaise and
12&#x000a0;g (13&#x000a0;ml) oil per d. Margarine was the only test product where
<italic>sn</italic>-1,3-DAG oil was added. Rapeseed oil was used in mayonnaise as TAG
(8&#x000b7;84&#x000a0;g/d), and in the margarine either as <italic>sn</italic>-1,3-DAG (11&#x000b7;2&#x000a0;g/d) and TAG
(2&#x000b7;88&#x000a0;g/d) (high-ALA-TAG group) or as TAG only (14&#x000b7;12&#x000a0;g/d) (high-ALA-TAG group) (<xref ref-type="table" rid="tab01">Table 1</xref>). The 12&#x000a0;g oil per d was the identical
flaxseed oil in the two groups in order to obtain a standardised and high level of ALA in
the diet. The products constituted in total approximately 35&#x000a0;g fat per d (<xref ref-type="table" rid="tab01">Table 1</xref>), corresponding to about 1255&#x000b7;2&#x000a0;kJ/d
(300&#x000a0;kcal/d). The food items were delivered at baseline and after 6 weeks of intervention.
At 4 weeks prior to the run-in period and during the intervention period, the subjects
were not allowed to use <italic>n</italic>-3 fatty acid supplements and other dietary
supplements. At each visit they were reminded by a nutritionist to keep a stable weight.
Fasting body weight and body composition measurements were registered at all visits. The
subjects were informed not to change the physical activity and dietary habit during the
study. The diet was registered at each visit using the SmartDiet questionnaire which is a
validated qualitative dietary questionnaire<sup>(</sup><xref rid="ref29" ref-type="bibr">
<sup>29</sup>
</xref><sup>)</sup>. <table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Fatty acid composition in the test products (g per portion<xref ref-type="table-fn" rid="tfn1_1">*</xref> and g per d)</p></caption><alternatives><graphic xlink:href="S2048679012000183_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-DAG (<italic>n</italic> 10)</th><th align="center" colspan="4" rowspan="1">High ALA-TAG (<italic>n</italic>
13)</th></tr><tr><th align="left" rowspan="1" colspan="1">(g)</th><th align="center" rowspan="1" colspan="1">Margarine</th><th align="center" rowspan="1" colspan="1">Mayonnaise</th><th align="center" rowspan="1" colspan="1">Oil&#x02020;</th><th align="center" rowspan="1" colspan="1">Per d</th><th align="center" rowspan="1" colspan="1">Margarine</th><th align="center" rowspan="1" colspan="1">Mayonnaise</th><th align="center" rowspan="1" colspan="1">Oil&#x02020;</th><th align="center" rowspan="1" colspan="1">Per d</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total fat</td><td rowspan="1" colspan="1">14&#x000b7;08</td><td rowspan="1" colspan="1">8&#x000b7;84</td><td rowspan="1" colspan="1">12&#x000b7;0</td><td rowspan="1" colspan="1">34&#x000b7;92</td><td rowspan="1" colspan="1">14&#x000b7;12</td><td rowspan="1" colspan="1">8&#x000b7;84</td><td rowspan="1" colspan="1">12&#x000b7;00</td><td rowspan="1" colspan="1">34&#x000b7;96</td></tr><tr><td rowspan="1" colspan="1">DAG</td><td rowspan="1" colspan="1">11&#x000b7;20</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">11&#x000b7;20</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">TAG</td><td rowspan="1" colspan="1">2&#x000b7;88</td><td rowspan="1" colspan="1">8&#x000b7;84</td><td rowspan="1" colspan="1">12&#x000b7;0</td><td rowspan="1" colspan="1">23&#x000b7;72</td><td rowspan="1" colspan="1">14&#x000b7;12</td><td rowspan="1" colspan="1">8&#x000b7;84</td><td rowspan="1" colspan="1">12&#x000b7;00</td><td rowspan="1" colspan="1">34&#x000b7;96</td></tr><tr><td rowspan="1" colspan="1">SFA</td><td rowspan="1" colspan="1">2&#x000b7;80</td><td rowspan="1" colspan="1">0&#x000b7;67</td><td rowspan="1" colspan="1">0&#x000b7;83</td><td rowspan="1" colspan="1">4&#x000b7;30</td><td rowspan="1" colspan="1">2&#x000b7;80</td><td rowspan="1" colspan="1">0&#x000b7;67</td><td rowspan="1" colspan="1">0&#x000b7;83</td><td rowspan="1" colspan="1">4&#x000b7;30</td></tr><tr><td rowspan="1" colspan="1">MUFA</td><td rowspan="1" colspan="1">7&#x000b7;40</td><td rowspan="1" colspan="1">5&#x000b7;06</td><td rowspan="1" colspan="1">1&#x000b7;80</td><td rowspan="1" colspan="1">14&#x000b7;26</td><td rowspan="1" colspan="1">7&#x000b7;20</td><td rowspan="1" colspan="1">5&#x000b7;06</td><td rowspan="1" colspan="1">1&#x000b7;80</td><td rowspan="1" colspan="1">14&#x000b7;06</td></tr><tr><td rowspan="1" colspan="1">18 : 3<italic>n</italic>-3 (ALA)</td><td rowspan="1" colspan="1">0&#x000b7;78</td><td rowspan="1" colspan="1">0&#x000b7;79</td><td rowspan="1" colspan="1">6&#x000b7;72</td><td rowspan="1" colspan="1">8&#x000b7;29</td><td rowspan="1" colspan="1">1&#x000b7;00</td><td rowspan="1" colspan="1">0&#x000b7;79</td><td rowspan="1" colspan="1">6&#x000b7;72</td><td rowspan="1" colspan="1">8&#x000b7;51</td></tr><tr><td rowspan="1" colspan="1">20 : 5n-3 (EPA)</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td rowspan="1" colspan="1">22 : 6<italic>n</italic>-3 (DHA)</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td rowspan="1" colspan="1">Total <italic>n</italic>-3</td><td rowspan="1" colspan="1">0&#x000b7;80</td><td rowspan="1" colspan="1">0&#x000b7;79</td><td rowspan="1" colspan="1">6&#x000b7;84</td><td rowspan="1" colspan="1">8&#x000b7;43</td><td rowspan="1" colspan="1">1&#x000b7;02</td><td rowspan="1" colspan="1">0&#x000b7;79</td><td rowspan="1" colspan="1">6&#x000b7;84</td><td rowspan="1" colspan="1">8&#x000b7;65</td></tr><tr><td rowspan="1" colspan="1">18 : 2<italic>n</italic>-6 (LA)</td><td rowspan="1" colspan="1">2&#x000b7;20</td><td rowspan="1" colspan="1">1&#x000b7;76</td><td rowspan="1" colspan="1">1&#x000b7;80</td><td rowspan="1" colspan="1">5&#x000b7;76</td><td rowspan="1" colspan="1">2&#x000b7;20</td><td rowspan="1" colspan="1">1&#x000b7;76</td><td rowspan="1" colspan="1">1&#x000b7;80</td><td rowspan="1" colspan="1">5&#x000b7;76</td></tr><tr><td rowspan="1" colspan="1">Vitamin E</td><td rowspan="1" colspan="1">6&#x000b7;20</td><td rowspan="1" colspan="1">1&#x000b7;54</td><td rowspan="1" colspan="1">11&#x000b7;32</td><td rowspan="1" colspan="1">19&#x000b7;06</td><td rowspan="1" colspan="1">3&#x000b7;26</td><td rowspan="1" colspan="1">1&#x000b7;54</td><td rowspan="1" colspan="1">11&#x000b7;32</td><td rowspan="1" colspan="1">16&#x000b7;12</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ALA, &#x003b1;-linolenic acid; DAG, diacylglycerol; LA, linoleic acid.</p></fn><fn id="tfn1_1"><label>*</label><p>One portion of margarine, mayonnaise and oil equals 20, 11 and 12&#x000a0;g,
respectively.</p></fn><fn><p>&#x02020; Flaxseed oil.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec1-2-1"><title>Blinding and randomisation</title><p>The present study was double-blinded by the identical appearance of different food
items; their contents were identifiable only by ID numbers on the food items.
Randomisation was performed by LINK Medical Research AS using Microsoft Excel and its
random generator.</p></sec><sec id="sec1-2-2"><title>Compliance</title><p>Participants were instructed to bring back food containers (lids of margarine, sachets
of mayonnaise and bottles of oil) and compliance was estimated by counting the empty
food containers and estimating the leftovers. We estimated compliance by dividing the
amount of leftovers by the total amount of food scheduled for the intervention period.
The mean compliance for each subject was expressed as a percentage. According to the
protocol, subjects with low compliance (&#x0003c;70&#x000a0;%) were excluded from the study.
Compliance was estimated to be 90&#x02013;100&#x000a0;% in both groups.</p></sec></sec><sec id="sec1-3"><title>Study products</title><p>Margarine and mayonnaise were based on commercial products manufactured by Mills DA.
Mayonnaise with 80&#x000a0;% fat was based on refined sunflower oil (Aarhus Karlshamn) for the
run-in period and refined rapeseed oil (Aarhus Karlshamn) for the high-ALA groups.
Mayonnaise was packed in commercial portion sachets of 11&#x000a0;g.</p><p>Margarine with 70&#x000a0;% fat was based on sunflower oil (run-in period), refined rapeseed oil
(AarhusKarlshamn AB) (high-ALA-TAG group) or rapeseed oil with DAG (Kao Corporation)
(high-ALA-DAG group), produced by Danisco AS. The margarine was packed in commercial lids,
140&#x000a0;g in each.</p><p>Refined sunflower oil (AarhusKarlshamn AB) (run-in period) was filled into green,
transparent polyethylene ferephthalate bottles of 500&#x000a0;ml. Cold pressed flaxseed oil (Norsk
Fropresse AS) (high-ALA groups) was fortified with vitamin E acetate from BASF in order to
obtain equal amounts of vitamin E for both groups and filled into identical bottles. The
participants were told to cover the bottles with aluminum foil and keep the oil
refrigerated.</p><p>The fatty acid profile and vitamin E in the products were analysed by the GC method in a
routine laboratory (Eurofins). Results are shown in <xref ref-type="table" rid="tab01">Table 1</xref>.</p></sec><sec id="sec1-4"><title>Measurements of body composition</title><p>Subjects wore light clothing and no shoes. Two trained persons carried out all
measurements. Height was measured by a wall-mounted stadiometer to the nearest 0&#x000b7;1&#x000a0;cm.
Weight was measured by the Tanita BC-418 manufactured by Tanita Corporation to the nearest
0&#x000b7;1&#x000a0;kg. To correct for light clothing, 1 kg was subtracted from the measured value. BMI
was calculated by the Tanita BC-418. Waist circumference and hip circumference were
measured to the nearest mm with a standard, non-stretch tape. Waist circumference was
measured at the point midway between the iliac crest and the lower rib margin. Hip
circumference was measured at the maximum circumference of the buttocks posterior and the
symphysis anterior. All subjects were measured while standing in a relaxed position and
with normal respiration. Body composition was estimated by bioelectric impedance analysis
(Tanita BC-418), a hand-to-foot system, according to the manufacturer's manual.
Information on age, height and body type (all were routinely classified as &#x02018;standard&#x02019; body
type) was entered before measuring. Bioelectric impedance analysis measurements were
carried out at a frequency of 50&#x000a0;kHz.</p></sec><sec id="sec1-5"><title>Blood and urine sampling</title><p>The day prior to blood sampling, the subjects were told to refrain from alcohol
consumption and vigorous physical activity; venous blood samples were drawn after an
overnight fast (&#x02265;12&#x000a0;h). Serum was obtained from silica gel tubes (Becton Dickinson
vacutainer) and kept at room temperature for at least 30&#x000a0;min, until centrifugation (1500&#x000a0;<bold><italic>g</italic></bold>, 12&#x000a0;min). Serum was kept at room temperature and immediately prepared for
subsequent analysis of routine laboratory analysis or aliquoted and stored at &#x02212;80&#x000b0;C until
further analyses. Plasma was obtained from EDTA tubes (Becton Dickinson vacutainer),
immediately placed on ice and centrifuged within 10&#x000a0;min (2000&#x000a0;<bold><italic>g</italic></bold>, 4&#x000b0;C). Plasma samples were aliquoted and stored at &#x02212;80&#x000b0;C until further analyses.
Morning spot urine samples were refrigerated (4&#x000b0;C) until aliquoted and stored at &#x02212;80&#x000b0;C
until further analysis.</p></sec><sec id="sec1-6"><title>Routine laboratory analysis</title><p>Fasting serum high-sensitivity CRP (hsCRP), total cholesterol, LDL-cholesterol,
HDL-cholesterol, TAG, glucose, C-peptide, insulin, HbA1c, thyroid-stimulating hormone,
&#x003b3;-GT, alkaline phosphatase (ALP), ALAT and aspartame aminotransferase (ASAT) were measured
by standard methods at a routine laboratory (F&#x000fc;rst Medical Laboratory). Fasting plasma
NEFA were measured by standard methods (Department of Medical Biochemistry, Rikshospitalet
University Hospital, Norway).</p><p>8-iso-PGF<sub>2&#x003b1;</sub> and creatinine in morning spot urine samples were determined by
Vitas AS. Urinary 8-iso-PGF<sub>2&#x003b1;</sub> was analysed by liquid chromatography with
negative electrospray ionisation coupled to tandem mass spectrometric detection according
to Bastani <italic>et al.</italic><sup>(</sup><xref rid="ref30" ref-type="bibr">
<sup>30</sup>
</xref><sup>)</sup>. Urinary levels of 8-iso-PGF<sub>2&#x003b1;</sub> are presented as the ratio
of 8-iso-PGF<sub>2&#x003b1;</sub> to creatinine. Urine creatinine was determined by ELISA using
the Cayman Chemical Creatinine Assay kit. The ninety-six-well plate format ELISA kit,
validated for urine samples, uses colorimetric detection at 495&#x000a0;nm. Assay range:
0&#x02013;150&#x000a0;mg/l (normal range 250&#x02013;4000&#x000a0;mg/l).</p><p>Plasma &#x003b1;-tocopherol analysis<sup>(</sup><xref rid="ref31" ref-type="bibr">
<sup>31</sup>
</xref><sup>)</sup> and quantification of fatty acids in plasma lipids<sup>(</sup><xref rid="ref32" ref-type="bibr">
<sup>32</sup>
</xref><sup>)</sup> were performed by Vitas AS.</p></sec><sec id="sec1-7"><title>Enzyme immunoassay</title><p>Serum was stored at &#x02212;80&#x000b0;C in multiple aliquots until analysis. Serum leptin, adiponectin,
resistin and fetuin-A were measured by enzyme immunoassay by R&#x00026;D Systems according
to the manufacturer's instructions.</p></sec><sec id="sec1-8"><title>Statistics</title><p>Sample size was calculated based on the existing literature primarily on the effects of
ALA on hsCRP in dietary intervention studies since this outcome measurement would require
the highest number of subjects. The calculations used an expected change in hsCRP from
baseline to the end of the study of 20 (<sc>sd</sc> 0&#x000b7;5)&#x000a0;%. The level of significance was
set to 5&#x000a0;% (two-sided) and the power to 80&#x000a0;%. A total of seventy-five subjects were
required in the main study (twenty-five per arm; three arms). Seventy-five subjects in
total were randomised, with forty-nine subjects being randomised to the present two
groups. Due to a high withdrawal rate, a total of twenty-three subjects completed the
study. Due to sample size, data were analysed with non-parametric tests and are presented
as median (25&#x02013;75 percentiles). Differences between the randomisation groups were analysed
at baseline and after 12 weeks of intervention (baseline adjusted values). The changes
between the two groups or within groups after 12 weeks of intervention were analysed by
the Mann&#x02013;Whitney <italic>U</italic> test or the Wilcoxon matched-pair signed-rank test,
respectively. Bonferroni correction to adjust for multiple testing was performed (adjusted
<italic>P</italic>&#x000a0;&#x02264;&#x000a0;0&#x000b7;001). Correlation analysis was performed using Spearman's
rank-order correlation. All analyses were performed using SPSS for Windows (version
19.0).</p></sec></sec><sec sec-type="results" id="sec2"><title>Results</title><p>In the present study, twenty-three healthy, overweight subjects (six women and seventeen
men) participated, randomised in two intervention groups. The subjects were 52 (<xref rid="ref45" ref-type="bibr">45</xref>&#x02013;<xref rid="ref62" ref-type="bibr">62</xref>) years,
with a median BMI of 30 (<xref rid="ref28" ref-type="bibr">28</xref>&#x02013;<xref rid="ref32" ref-type="bibr">32</xref>)&#x000a0;kg/m<sup>2</sup>. At baseline there were no differences in age
between the intervention groups.</p><sec id="sec2-1"><title>Body composition</title><p>At baseline there were no significant differences in blood pressure and body composition
(total body fat percentage, total body fat mass, trunk fat mass and fat-free mass (FFM))
between the intervention groups. Prior to Bonferroni adjustment, there was a significant
difference between the two groups in weight, BMI and waist circumference at baseline
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03, 0&#x000b7;05 and 0&#x000b7;01, respectively); however, these differences
disappeared after Bonferroni adjustment (<xref ref-type="table" rid="tab02">Table
2</xref>). <table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Clinical characteristics and body composition at baseline and after 12 weeks of
intervention (Medians and 25th&#x02013;75th percentiles)</p></caption><alternatives><graphic xlink:href="S2048679012000183_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="center" width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-DAG (<italic>n</italic> 10)</th><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-TAG (<italic>n</italic> 13)</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">
<italic>P*</italic>
</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02021;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex (<italic>n</italic>)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">45&#x02013;65</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">43&#x02013;60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">Systolic BP (mmHg)</td><td rowspan="1" colspan="1">135</td><td rowspan="1" colspan="1">121&#x02013;144</td><td rowspan="1" colspan="1">126</td><td rowspan="1" colspan="1">121&#x02013;136</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">126&#x02013;154</td><td rowspan="1" colspan="1">141</td><td rowspan="1" colspan="1">134&#x02013;149</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;05</td></tr><tr><td rowspan="1" colspan="1">Diastolic BP (mmHg)</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">77&#x02013;88</td><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">76&#x02013;92</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">77&#x02013;89</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">84&#x02013;91</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">86&#x000b7;3</td><td rowspan="1" colspan="1">80&#x000b7;2&#x02013;102&#x000b7;9</td><td rowspan="1" colspan="1">87&#x000b7;2</td><td rowspan="1" colspan="1">80&#x000b7;9&#x02013;104&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;07</td><td rowspan="1" colspan="1">95&#x000b7;9</td><td rowspan="1" colspan="1">91&#x000b7;7&#x02013;106&#x000b7;9</td><td rowspan="1" colspan="1">97.5</td><td rowspan="1" colspan="1">91&#x000b7;6&#x02013;106&#x000b7;0</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">28&#x02013;31</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">28&#x02013;32</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">30&#x02013;33</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">30&#x02013;33</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">Waist (cm)</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">96&#x02013;109</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">96&#x02013;107</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">107</td><td rowspan="1" colspan="1">102&#x02013;116</td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">103&#x02013;114</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td rowspan="1" colspan="1">Hip (cm)</td><td rowspan="1" colspan="1">106</td><td rowspan="1" colspan="1">103&#x02013;110</td><td rowspan="1" colspan="1">106</td><td rowspan="1" colspan="1">102&#x02013;109</td><td rowspan="1" colspan="1">0&#x000b7;4</td><td rowspan="1" colspan="1">108</td><td rowspan="1" colspan="1">105&#x02013;114</td><td rowspan="1" colspan="1">111</td><td rowspan="1" colspan="1">105&#x02013;115</td><td rowspan="1" colspan="1">0&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td rowspan="1" colspan="1">Waist:hip ratio</td><td rowspan="1" colspan="1">0&#x000b7;90</td><td rowspan="1" colspan="1">0&#x000b7;90&#x02013;1&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;95</td><td rowspan="1" colspan="1">0&#x000b7;90&#x02013;1&#x000b7;00</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;00</td><td rowspan="1" colspan="1">0&#x000b7;95&#x02013;1&#x000b7;05</td><td rowspan="1" colspan="1">1&#x000b7;00</td><td rowspan="1" colspan="1">0&#x000b7;90&#x02013;1&#x000b7;00</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td rowspan="1" colspan="1">Fat %</td><td rowspan="1" colspan="1">29&#x000b7;3</td><td rowspan="1" colspan="1">23&#x000b7;6&#x02013;41&#x000b7;3</td><td rowspan="1" colspan="1">28&#x000b7;4</td><td rowspan="1" colspan="1">23&#x000b7;0&#x02013;40&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;04</td><td rowspan="1" colspan="1">31&#x000b7;0</td><td rowspan="1" colspan="1">26&#x000b7;8&#x02013;33&#x000b7;8</td><td rowspan="1" colspan="1">31&#x000b7;5</td><td rowspan="1" colspan="1">26&#x000b7;3&#x02013;33&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td rowspan="1" colspan="1">Total body fat (kg)</td><td rowspan="1" colspan="1">28&#x000b7;8</td><td rowspan="1" colspan="1">20&#x000b7;5&#x02013;34&#x000b7;1</td><td rowspan="1" colspan="1">29&#x000b7;0</td><td rowspan="1" colspan="1">20&#x000b7;2&#x02013;32&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;09</td><td rowspan="1" colspan="1">29&#x000b7;1</td><td rowspan="1" colspan="1">24&#x000b7;7&#x02013;37&#x000b7;2</td><td rowspan="1" colspan="1">29&#x000b7;9</td><td rowspan="1" colspan="1">25&#x000b7;5&#x02013;37&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">Trunk fat (kg)</td><td rowspan="1" colspan="1">16&#x000b7;0</td><td rowspan="1" colspan="1">12&#x000b7;8&#x02013;19&#x000b7;1</td><td rowspan="1" colspan="1">15&#x000b7;1</td><td rowspan="1" colspan="1">12&#x000b7;6&#x02013;19&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">18&#x000b7;3</td><td rowspan="1" colspan="1">15&#x000b7;3&#x02013;21&#x000b7;3</td><td rowspan="1" colspan="1">17&#x000b7;9</td><td rowspan="1" colspan="1">15&#x000b7;8&#x02013;21&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;04</td></tr><tr><td rowspan="1" colspan="1">FFM (kg)</td><td rowspan="1" colspan="1">63&#x000b7;8</td><td rowspan="1" colspan="1">47&#x000b7;0&#x02013;69&#x000b7;1</td><td rowspan="1" colspan="1">65&#x000b7;1</td><td rowspan="1" colspan="1">48&#x000b7;5&#x02013;71&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">70&#x000b7;2</td><td rowspan="1" colspan="1">60&#x000b7;6&#x02013;74&#x000b7;8</td><td rowspan="1" colspan="1">70&#x000b7;3</td><td rowspan="1" colspan="1">60&#x000b7;7&#x02013;73&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;06</td></tr><tr><td rowspan="1" colspan="1">Fat %:weight ratio</td><td rowspan="1" colspan="1">0&#x000b7;31</td><td rowspan="1" colspan="1">0&#x000b7;26&#x02013;0&#x000b7;52</td><td rowspan="1" colspan="1">0&#x000b7;30</td><td rowspan="1" colspan="1">0&#x000b7;26&#x02013;0&#x000b7;49</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">0&#x000b7;30</td><td rowspan="1" colspan="1">0&#x000b7;27&#x02013;0&#x000b7;37</td><td rowspan="1" colspan="1">0&#x000b7;28</td><td rowspan="1" colspan="1">0&#x000b7;27&#x02013;0&#x000b7;36</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;03</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ALA, &#x003b1;-linolenic acid; DAG, diacylglycerol; BP, blood pressure; FFM, fat-free
mass.</p></fn><fn><p>* Within the high-ALA-DAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02020; Within the high-ALA-TAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02021; Comparing change from baseline to the end of the study between the high-ALA-DAG
and high-ALA-TAG groups (prior to Bonferroni correction).</p></fn></table-wrap-foot></table-wrap></p><p>Since intake of DAG oil has been associated with weight loss, we investigated the effect
on weight change. After 12 weeks of intervention, body weight did not change between or
within the two groups. However, there was a non-significant trend towards an increase in
weight in the high-ALA-DAG group (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;07). We also investigated the
effect on body composition. Prior to Bonferroni adjustment, there was a significant
decrease in both total body fat percentage and trunk fat mass within the high-ALA-DAG
group from baseline to 12 weeks of intervention (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04 and 0&#x000b7;05,
respectively) and this decrease was significantly different from the effect observed in
the high-ALA-TAG group (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03 and 0&#x000b7;04, respectively). There was no
significant change within or between the groups in total body fat mass. Concomitantly,
there was a significant increase in the amount of FFM within the high-ALA-DAG group
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;016) from baseline to the end of the study and this change in
FFM was borderline significant (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;06) between the two groups (<xref ref-type="table" rid="tab02">Table 2</xref>). All differences disappeared after
Bonferroni adjustment.</p></sec><sec id="sec3-2"><title>Blood pressure</title><p>Systolic and diastolic blood pressure was measured at baseline and after 12 weeks of
intervention (<xref ref-type="table" rid="tab02">Table 2</xref>). Prior to Bonferroni
adjustment, there was a significant decrease in systolic blood pressure within the
high-ALA-DAG group (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;05) after intervention, and the change in
systolic blood pressure was significantly different between the two groups
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;05); however, this was non-significant after Bonferroni
adjustment. There was no significant difference in diastolic blood pressure after 12 weeks
of intervention between or within any of the groups (<xref ref-type="table" rid="tab02">Table 2</xref>).</p></sec><sec id="sec3-3"><title>Serum lipids, C-reactive protein and insulin sensitivity markers</title><p>At baseline, no differences in serum levels of hsCRP, glucose, insulin, C-peptide, HbA1c,
total cholesterol, LDL-cholesterol, HDL-cholesterol and TAG between the intervention
groups were observed (<xref ref-type="table" rid="tab03">Table 3</xref>). Baseline values
of homeostatic model assessment for insulin resistance (HOMA-IR) were significantly
different between the two groups (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;05). After 12 weeks of
intervention, there was no significant difference in the serum hsCRP, glucose, insulin,
HOMA-IR, C-peptide, HbA1c, total cholesterol, HDL-cholesterol and TAG between or within
the two groups (<xref ref-type="table" rid="tab03">Table 3</xref>). However, after 12
weeks of intervention, there was a non-significant (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;06) difference
in LDL-cholesterol between the high-ALA groups, with a non-significant decrease in the
high-ALA-DAG group (4&#x000b7;0&#x02013;3&#x000b7;7&#x000a0;mmol/l) and a non-significant increase in the high-ALA-TAG
group (3&#x000b7;3&#x02013;3&#x000b7;6&#x000a0;mmol/l) (<xref ref-type="table" rid="tab03">Table 3</xref>). All
significant differences disappeared after Bonferroni adjustment. <table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Plasma lipids and biochemical measurements at baseline and after 12 weeks of
intervention (Medians and 25th&#x02013;75th percentiles)</p></caption><alternatives><graphic xlink:href="S2048679012000183_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="center" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="center" width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-DAG (<italic>n</italic> 10)</th><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-TAG (<italic>n</italic> 13)</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>*</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02021;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total cholesterol (mmol/l)</td><td rowspan="1" colspan="1">5&#x000b7;9</td><td rowspan="1" colspan="1">5&#x000b7;2&#x02013;6&#x000b7;2</td><td rowspan="1" colspan="1">5&#x000b7;6</td><td rowspan="1" colspan="1">4&#x000b7;9&#x02013;6&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">5&#x000b7;4</td><td rowspan="1" colspan="1">5&#x000b7;1&#x02013;5&#x000b7;8</td><td rowspan="1" colspan="1">5&#x000b7;4</td><td rowspan="1" colspan="1">5&#x000b7;0&#x02013;6&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">LDL-cholesterol (mmol/l)</td><td rowspan="1" colspan="1">4&#x000b7;0</td><td rowspan="1" colspan="1">3&#x000b7;1&#x02013;4&#x000b7;3</td><td rowspan="1" colspan="1">3&#x000b7;7</td><td rowspan="1" colspan="1">3&#x000b7;0&#x02013;4&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">3&#x000b7;3</td><td rowspan="1" colspan="1">3&#x000b7;1&#x02013;3&#x000b7;8</td><td rowspan="1" colspan="1">3&#x000b7;6</td><td rowspan="1" colspan="1">3&#x000b7;1&#x02013;4&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;06</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol (mmol/l)</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;2&#x02013;1&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;1&#x02013;1&#x000b7;50</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;1&#x02013;1&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;0&#x02013;1&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td rowspan="1" colspan="1">TAG (mmol/l)</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;0&#x02013;1&#x000b7;7</td><td rowspan="1" colspan="1">1&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;0&#x02013;1&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;3&#x02013;2&#x000b7;0</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;4&#x02013;2&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td rowspan="1" colspan="1">NEFA (&#x003bc;mol/l)</td><td rowspan="1" colspan="1">0&#x000b7;53</td><td rowspan="1" colspan="1">0&#x000b7;44&#x02013;0&#x000b7;60</td><td rowspan="1" colspan="1">0&#x000b7;40</td><td rowspan="1" colspan="1">0&#x000b7;33&#x02013;0&#x000b7;54</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;43</td><td rowspan="1" colspan="1">0&#x000b7;34&#x02013;0&#x000b7;58</td><td rowspan="1" colspan="1">0&#x000b7;53</td><td rowspan="1" colspan="1">0&#x000b7;40&#x02013;0&#x000b7;63</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;02</td></tr><tr><td rowspan="1" colspan="1">ApoA-1 (g/l)</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;3&#x02013;1&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;3&#x02013;1&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;3&#x02013;1&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;4</td><td rowspan="1" colspan="1">1&#x000b7;3&#x02013;1&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">ApoB (g/l)</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;7&#x02013;1&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;8&#x02013;1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;8&#x02013;1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;9&#x02013;1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">Glucose (mmol/l)</td><td rowspan="1" colspan="1">5&#x000b7;5</td><td rowspan="1" colspan="1">5&#x000b7;0&#x02013;5&#x000b7;9</td><td rowspan="1" colspan="1">5&#x000b7;5</td><td rowspan="1" colspan="1">5&#x000b7;2&#x02013;5&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">5&#x000b7;8</td><td rowspan="1" colspan="1">5&#x000b7;4&#x02013;6&#x000b7;2</td><td rowspan="1" colspan="1">5&#x000b7;5</td><td rowspan="1" colspan="1">5&#x000b7;3&#x02013;6&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">Insulin (pmol/l)</td><td rowspan="1" colspan="1">61&#x000b7;5</td><td rowspan="1" colspan="1">45&#x000b7;0&#x02013;81&#x000b7;3</td><td rowspan="1" colspan="1">63&#x000b7;0</td><td rowspan="1" colspan="1">50&#x000b7;5&#x02013;79&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">80&#x000b7;0</td><td rowspan="1" colspan="1">63&#x000b7;0&#x02013;109&#x000b7;0</td><td rowspan="1" colspan="1">83&#x000b7;0</td><td rowspan="1" colspan="1">48&#x000b7;0&#x02013;116&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td rowspan="1" colspan="1">5&#x000b7;6</td><td rowspan="1" colspan="1">5&#x000b7;3&#x02013;5&#x000b7;9</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">5&#x000b7;5&#x02013;5&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">5&#x000b7;5</td><td rowspan="1" colspan="1">5&#x000b7;3&#x02013;6&#x000b7;0</td><td rowspan="1" colspan="1">5&#x000b7;7</td><td rowspan="1" colspan="1">5&#x000b7;4&#x02013;5&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">C-peptide (pmol/l)</td><td rowspan="1" colspan="1">900</td><td rowspan="1" colspan="1">735&#x02013;1097</td><td rowspan="1" colspan="1">883</td><td rowspan="1" colspan="1">805&#x02013;1063</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">994</td><td rowspan="1" colspan="1">792&#x02013;1270</td><td rowspan="1" colspan="1">1021</td><td rowspan="1" colspan="1">802&#x02013;1278</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td rowspan="1" colspan="1">HOMA<sub>ir</sub>&#x000a7;</td><td rowspan="1" colspan="1">2&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;6&#x02013;3&#x000b7;0</td><td rowspan="1" colspan="1">2&#x000b7;3</td><td rowspan="1" colspan="1">1&#x000b7;6&#x02013;2&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">3&#x000b7;0</td><td rowspan="1" colspan="1">2&#x000b7;2&#x02013;3&#x000b7;8</td><td rowspan="1" colspan="1">3&#x000b7;0</td><td rowspan="1" colspan="1">1&#x000b7;9&#x02013;4&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td rowspan="1" colspan="1">hsCRP (mg/l)</td><td rowspan="1" colspan="1">1&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;3&#x02013;3&#x000b7;1</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;1&#x02013;1&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">1&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;7&#x02013;2&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;7&#x02013;2&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">TSH (mU/l)</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;9&#x02013;2&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;8&#x02013;1&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;1&#x02013;1&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;6</td><td rowspan="1" colspan="1">1&#x000b7;3&#x02013;2&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;4</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ALA, &#x003b1;-linolenic acid; DAG, diacylglycerol; HOMA<sub>ir</sub>, homeostasis model
assessment for insulin resistance; hsCRP, high-sensitivity C-reactive protein;
TSH, thyroid-stimulating hormone.</p></fn><fn><p>* Within the high-ALA-DAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02020; Within the high-ALA-TAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02021; Comparing change from baseline to the end of the study between the high-ALA-DAG
and high-ALA-TAG groups (prior to Bonferroni correction).</p></fn><fn><p>&#x000a7; HOMA<sub>ir</sub>&#x000a0;=&#x000a0;(fasting plasma insulin (mU/l)&#x000a0;&#x000d7;&#x000a0;fasting plasma glucose
(mmol/l))/22&#x000b7;5, where 1 mU/l&#x000a0;=&#x000a0;6&#x000b7;945&#x000a0;pmol/l.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-4"><title>Circulating NEFA</title><p>Circulating NEFA have been shown to be elevated in obese subjects; we therefore measured
fasting plasma NEFA concentrations. At baseline, there was no difference in the NEFA
concentration between the intervention groups (<xref ref-type="table" rid="tab03">Table
3</xref>). The changes in circulating fasting NEFA concentration were non-significantly
(after Bonferroni adjustment) different (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;02) between the two groups
after 12 weeks of intervention, with a non-significant decrease within the high-ALA-DAG
group and a non-significant increase within the high-ALA-TAG group (<xref ref-type="table" rid="tab03">Table 3</xref>).</p></sec><sec id="sec3-5"><title>Liver function parameters</title><p>Obesity leads to accumulation of fatty acids in the liver and therefore we measured
markers of liver function such as ASAT, ALAT, &#x003b3;-GT and ALP. At baseline no differences in
these markers between the intervention groups were observed (<xref ref-type="table" rid="tab04">Table 4</xref>). However, prior to Bonferroni adjustment, the concentration
of ALAT, &#x003b3;-GT and ALP was significantly reduced within the high-ALA-DAG group
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;02, 0&#x000b7;02 and 0&#x000b7;01, respectively) and the change in ALAT was
significantly different from the high-ALA-TAG group (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;02), whereas
the change in &#x003b3;-GT and ALP was not significantly different from the high-ALA-TAG group
(<xref ref-type="table" rid="tab04">Table 4</xref>). These differences disappeared after
Bonferroni adjustment. No significant differences within or between the groups in the
ASAT:ALAT ratio after 12 weeks of intervention were observed (data not shown). The change
in ALAT was positively correlated with the change in trunk fat mass (<italic>r</italic>
0&#x000b7;5; <italic>P</italic> =&#x000a0;0&#x000b7;007) and total body fat mass (<italic>r</italic> 0&#x000b7;5;
<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03) in the groups calculated together. The change in &#x003b3;-GT and ALP
did not correlate with the change in total body fat mass or trunk fat mass in any of the
groups. In addition, we measured the serum concentration of fetuin-A, a suggested marker
for hepatic steatosis<sup>(</sup><xref rid="ref33" ref-type="bibr">
<sup>33</sup>
</xref><sup>)</sup>. However, no changes in serum concentration of fetuin-A were found
within or between the groups (<xref ref-type="table" rid="tab04">Table 4</xref>).
<table-wrap id="tab04" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Plasma liver function markers at baseline and after 12 weeks of intervention
(Medians and 25th&#x02013;75th percentiles)</p></caption><alternatives><graphic xlink:href="S2048679012000183_tab4"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-DAG (<italic>n</italic> 10)</th><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-TAG (<italic>n</italic> 13)</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>*</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02021;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ASAT (U/l)</td><td rowspan="1" colspan="1">25&#x000b7;5</td><td rowspan="1" colspan="1">23&#x000b7;0&#x02013;32&#x000b7;3</td><td rowspan="1" colspan="1">25&#x000b7;5</td><td rowspan="1" colspan="1">22&#x000b7;8&#x02013;29&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">27&#x000b7;0</td><td rowspan="1" colspan="1">24&#x000b7;0&#x02013;28&#x000b7;0</td><td rowspan="1" colspan="1">27&#x000b7;0</td><td rowspan="1" colspan="1">24&#x000b7;0&#x02013;31&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">ALAT (U/l)</td><td rowspan="1" colspan="1">29&#x000b7;0</td><td rowspan="1" colspan="1">20&#x000b7;5&#x02013;37&#x000b7;5</td><td rowspan="1" colspan="1">24&#x000b7;5</td><td rowspan="1" colspan="1">19&#x000b7;5&#x02013;31&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">28&#x000b7;0</td><td rowspan="1" colspan="1">22&#x000b7;5&#x02013;37&#x000b7;0</td><td rowspan="1" colspan="1">27&#x000b7;0</td><td rowspan="1" colspan="1">22&#x000b7;0&#x02013;38&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;02</td></tr><tr><td rowspan="1" colspan="1">&#x003b3;GT (U/l)</td><td rowspan="1" colspan="1">24&#x000b7;0</td><td rowspan="1" colspan="1">18&#x000b7;5&#x02013;32&#x000b7;0</td><td rowspan="1" colspan="1">19&#x000b7;0</td><td rowspan="1" colspan="1">14&#x000b7;0&#x02013;28&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">32&#x000b7;0</td><td rowspan="1" colspan="1">22&#x000b7;0&#x02013;48&#x000b7;5</td><td rowspan="1" colspan="1">30&#x000b7;0</td><td rowspan="1" colspan="1">21&#x000b7;5&#x02013;63&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td rowspan="1" colspan="1">ALP (U/l)</td><td rowspan="1" colspan="1">71&#x000b7;0</td><td rowspan="1" colspan="1">63&#x000b7;5&#x02013;75&#x000b7;0</td><td rowspan="1" colspan="1">63&#x000b7;5</td><td rowspan="1" colspan="1">56&#x000b7;3&#x02013;69&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;01</td><td rowspan="1" colspan="1">62&#x000b7;0</td><td rowspan="1" colspan="1">57&#x000b7;0&#x02013;76&#x000b7;0</td><td rowspan="1" colspan="1">64&#x000b7;0</td><td rowspan="1" colspan="1">53&#x000b7;0&#x02013;85&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">Fetuin-A (&#x000b5;g/ml)</td><td rowspan="1" colspan="1">478&#x000b7;2</td><td rowspan="1" colspan="1">360&#x000b7;0&#x02013;592&#x000b7;6</td><td rowspan="1" colspan="1">452&#x000b7;2</td><td rowspan="1" colspan="1">348&#x000b7;1&#x02013;514&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">446&#x000b7;6</td><td rowspan="1" colspan="1">368&#x000b7;8&#x02013;498&#x000b7;6</td><td rowspan="1" colspan="1">441&#x000b7;8</td><td rowspan="1" colspan="1">326&#x000b7;2&#x02013;587&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ALA, &#x003b1;-linolenic acid; DAG, diacylglycerol; ASAT, aspartate aminotransferase;
ALAT, alanine aminotransferase; &#x003b3;GT, &#x003b3;-glutamyl transpeptidase; ALP, alkaline
phosphatase.</p></fn><fn><p>* Within the high-ALA-DAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02020; Within the high-ALA-TAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02021; Comparing change from baseline to the end of the study between the high-ALA-DAG
and high-ALA-TAG groups (prior to Bonferroni correction).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-6"><title>Adipokines in serum and plasma</title><p>Adipokines are secreted from adipose tissue and since intake of DAG oil has been shown to
influence body composition, we measured the circulating hormones leptin, resistin and
adiponectin. Despite a non-significant decrease in total body fat percentage and trunk fat
mass, no changes between or within any of the groups were observed in any of these
hormones after 12 weeks of intervention (<xref ref-type="table" rid="tab05">Table
5</xref>). Also, there were no correlations between the change in hormones and total body
fat mass or trunk fat mass. <table-wrap id="tab05" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Adipokines and oxidative stress markers in serum and plasma at baseline and after
12 weeks of intervention (Medians and 25th&#x02013;75th percentiles)</p></caption><alternatives><graphic xlink:href="S2048679012000183_tab5"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="(" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-DAG (<italic>n</italic> 10)</th><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-TAG (<italic>n</italic> 13)</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>*</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02021;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Adiponectin (ng/ml)</td><td rowspan="1" colspan="1">2163</td><td rowspan="1" colspan="1">1689&#x02013;3796</td><td rowspan="1" colspan="1">1982</td><td rowspan="1" colspan="1">1542&#x02013;4046</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">2491</td><td rowspan="1" colspan="1">2253&#x02013;3373</td><td rowspan="1" colspan="1">2530</td><td rowspan="1" colspan="1">2345&#x02013;3069</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td rowspan="1" colspan="1">Leptin (ng/ml)</td><td rowspan="1" colspan="1">8&#x000b7;1</td><td rowspan="1" colspan="1">4&#x000b7;5&#x02013;34&#x000b7;5</td><td rowspan="1" colspan="1">10&#x000b7;7</td><td rowspan="1" colspan="1">4&#x000b7;7&#x02013;28&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">12&#x000b7;9</td><td rowspan="1" colspan="1">7&#x000b7;0&#x02013;24&#x000b7;4</td><td rowspan="1" colspan="1">13&#x000b7;7</td><td rowspan="1" colspan="1">6&#x000b7;9&#x02013;26&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td rowspan="1" colspan="1">Resistin (ng/ml)</td><td rowspan="1" colspan="1">10&#x000b7;6</td><td rowspan="1" colspan="1">9&#x000b7;3&#x02013;13&#x000b7;6</td><td rowspan="1" colspan="1">10&#x000b7;5</td><td rowspan="1" colspan="1">9&#x000b7;5&#x02013;13&#x000b7;7</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">10&#x000b7;7</td><td rowspan="1" colspan="1">7&#x000b7;7&#x02013;12&#x000b7;5</td><td rowspan="1" colspan="1">11&#x000b7;6</td><td rowspan="1" colspan="1">8&#x000b7;1&#x02013;12&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">Urine 8-iso-PGF<sub>2&#x003b1;</sub> (ng/g creatinine)</td><td rowspan="1" colspan="1">161&#x000b7;1</td><td rowspan="1" colspan="1">118&#x000b7;7&#x02013;243&#x000b7;4</td><td rowspan="1" colspan="1">178&#x000b7;3</td><td rowspan="1" colspan="1">134&#x000b7;6&#x02013;272&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">244&#x000b7;3</td><td rowspan="1" colspan="1">157&#x000b7;1&#x02013;306&#x000b7;0</td><td rowspan="1" colspan="1">255&#x000b7;8</td><td rowspan="1" colspan="1">162&#x000b7;9&#x02013;352&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">&#x003b1;-Tocopherol:total lipids&#x000a7;</td><td rowspan="1" colspan="1">6&#x000b7;5</td><td rowspan="1" colspan="1">5&#x000b7;5&#x02013;6&#x000b7;8</td><td rowspan="1" colspan="1">4&#x000b7;3</td><td rowspan="1" colspan="1">3&#x000b7;8&#x02013;4&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">5&#x000b7;9</td><td rowspan="1" colspan="1">4&#x000b7;9&#x02013;6&#x000b7;7</td><td rowspan="1" colspan="1">5&#x000b7;0</td><td rowspan="1" colspan="1">4&#x000b7;3&#x02013;5&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;05</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ALA, &#x003b1;-linolenic acid; DAG, diacylglycerol.</p></fn><fn><p>* Within the high-ALA-DAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02020; Within the high-ALA-TAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02021; Comparing change from baseline to the end of the study between the high-ALA-DAG
and high-ALA-TAG groups (prior to Bonferroni correction).</p></fn><fn><p>&#x000a7; The plasma concentration of &#x003b1;-tocopherol is normalised to the &#x003b1;-tocopherol to
total lipid concentration (&#x003b1;-tocopherol/total cholesterol&#x000a0;+&#x000a0;TAG), expressed as the
plasma &#x003b1;-tocopherol:plasma total lipid ratio.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-7"><title>Oxidative stress markers</title><p>Since ALA has been shown to be rapidly oxidised<sup>(</sup><xref rid="ref34" ref-type="bibr">
<sup>34</sup>
</xref><sup>)</sup>, we measured the oxidative stress markers urinary
8-iso-PGF<sub>2&#x003b1;</sub> and the antioxidant vitamin E. No significant changes between or
within the groups were observed for urinary 8-iso-PGF<sub>2&#x003b1;</sub> after 12 weeks of
intervention (<xref ref-type="table" rid="tab05">Table 5</xref>). Prior to Bonferroni
adjustment, the ratio of &#x003b1;-tocopherol:total lipids was significantly reduced within the
high-ALA-DAG group (<italic>P</italic> =&#x000a0;0&#x000b7;02) and the high-ALA-TAG group
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;05), with no significant difference between the groups after 12
weeks of intervention (<xref ref-type="table" rid="tab05">Table 5</xref>). These
differences disappeared after Bonferroni adjustment.</p></sec><sec id="sec3-8"><title>Fatty acid composition in plasma</title><p>The fatty acid composition in plasma was measured and is shown in <xref ref-type="table" rid="tab06">Table 6</xref>. Prior to Bonferroni adjustment, a significant increase in
ALA was observed both within the high-ALA-DAG (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;005) and the
high-ALA-TAG groups (<italic>P</italic> =&#x000a0;0&#x000b7;002) (<xref ref-type="table" rid="tab06">Table
6</xref>). The change in plasma ALA between the groups was significantly different
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04) after 12 weeks of intervention, with the largest increase
observed in the high-ALA-TAG group. Plasma EPA (20 : 5<italic>n</italic>-3) was
significantly increased within both groups (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04 and 0&#x000b7;02,
respectively), but the change was not significantly different between the groups. No
increase was observed in plasma DHA (22 : 6<italic>n</italic>-3) either within or between
the two groups. Linoleic acid (18 : 2<italic>n</italic>-6) was significantly reduced
within both groups (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;03 in both groups) after 12 weeks of
intervention, but there was no significant difference between them. Arachidonic acid (20 :
4<italic>n</italic>-6) was not changed within any of the groups, but a significant
change between the two groups (<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;05) was found. Minor changes were
observed among the other fatty acids (<xref ref-type="table" rid="tab06">Table 6</xref>).
All these differences disappeared after Bonferroni adjustment. <table-wrap id="tab06" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Fatty acid composition (&#x000b5;g/ml) in plasma at baseline and after 12 weeks of
intervention (Medians and 25th&#x02013;75th percentiles)</p></caption><alternatives><graphic xlink:href="S2048679012000183_tab6"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><col align="char" char="." width="1*" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-DAG (<italic>n</italic> 10)</th><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">High ALA-TAG (<italic>n</italic> 13)</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">End of study</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>*</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">25th&#x02013;75th percentiles</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02020;</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>&#x02021;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">14 : 0</td><td rowspan="1" colspan="1">25&#x000b7;8</td><td rowspan="1" colspan="1">21&#x000b7;4&#x02013;32&#x000b7;4</td><td rowspan="1" colspan="1">25&#x000b7;1</td><td rowspan="1" colspan="1">20&#x000b7;2&#x02013;31&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">33&#x000b7;0</td><td rowspan="1" colspan="1">22&#x000b7;8&#x02013;40&#x000b7;3</td><td rowspan="1" colspan="1">33&#x000b7;2</td><td rowspan="1" colspan="1">27&#x000b7;1&#x02013;45&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">15 : 0</td><td rowspan="1" colspan="1">5&#x000b7;9</td><td rowspan="1" colspan="1">5&#x000b7;1&#x02013;6&#x000b7;7</td><td rowspan="1" colspan="1">6&#x000b7;1</td><td rowspan="1" colspan="1">4&#x000b7;7&#x02013;6&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">6&#x000b7;4</td><td rowspan="1" colspan="1">5&#x000b7;3&#x02013;7&#x000b7;5</td><td rowspan="1" colspan="1">6&#x000b7;7</td><td rowspan="1" colspan="1">5&#x000b7;3&#x02013;7&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td rowspan="1" colspan="1">16 : 0</td><td rowspan="1" colspan="1">690&#x000b7;7</td><td rowspan="1" colspan="1">607&#x000b7;0&#x02013;802&#x000b7;4</td><td rowspan="1" colspan="1">691&#x000b7;5</td><td rowspan="1" colspan="1">570&#x000b7;0&#x02013;754&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;4</td><td rowspan="1" colspan="1">741&#x000b7;3</td><td rowspan="1" colspan="1">655&#x000b7;6&#x02013;891&#x000b7;5</td><td rowspan="1" colspan="1">789&#x000b7;1</td><td rowspan="1" colspan="1">689&#x000b7;2&#x02013;877&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">18 : 0</td><td rowspan="1" colspan="1">233&#x000b7;8</td><td rowspan="1" colspan="1">196&#x000b7;5&#x02013;252&#x000b7;4</td><td rowspan="1" colspan="1">216&#x000b7;8</td><td rowspan="1" colspan="1">199&#x000b7;7&#x02013;228&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;06</td><td rowspan="1" colspan="1">250&#x000b7;2</td><td rowspan="1" colspan="1">206&#x000b7;1&#x02013;274&#x000b7;1</td><td rowspan="1" colspan="1">253&#x000b7;8</td><td rowspan="1" colspan="1">202&#x000b7;8&#x02013;278&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">20 : 0</td><td rowspan="1" colspan="1">8&#x000b7;3</td><td rowspan="1" colspan="1">6&#x000b7;8&#x02013;9&#x000b7;3</td><td rowspan="1" colspan="1">8&#x000b7;4</td><td rowspan="1" colspan="1">6&#x000b7;9&#x02013;8&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">8&#x000b7;2</td><td rowspan="1" colspan="1">7&#x000b7;4&#x02013;9&#x000b7;8</td><td rowspan="1" colspan="1">9&#x000b7;1</td><td rowspan="1" colspan="1">8&#x000b7;1&#x02013;9&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">22 : 0</td><td rowspan="1" colspan="1">31&#x000b7;3</td><td rowspan="1" colspan="1">23&#x000b7;5&#x02013;32&#x000b7;6</td><td rowspan="1" colspan="1">27&#x000b7;5</td><td rowspan="1" colspan="1">23&#x000b7;2&#x02013;28&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">24&#x000b7;9</td><td rowspan="1" colspan="1">23&#x000b7;1&#x02013;29&#x000b7;8</td><td rowspan="1" colspan="1">25&#x000b7;6</td><td rowspan="1" colspan="1">21&#x000b7;0&#x02013;27&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">23 : 0</td><td rowspan="1" colspan="1">10&#x000b7;8</td><td rowspan="1" colspan="1">9&#x000b7;0&#x02013;12&#x000b7;6</td><td rowspan="1" colspan="1">10&#x000b7;0</td><td rowspan="1" colspan="1">9&#x000b7;3&#x02013;13&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">9&#x000b7;3</td><td rowspan="1" colspan="1">8&#x000b7;9&#x02013;11&#x000b7;0</td><td rowspan="1" colspan="1">10&#x000b7;7</td><td rowspan="1" colspan="1">9&#x000b7;0&#x02013;11&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">24 : 0</td><td rowspan="1" colspan="1">30&#x000b7;3</td><td rowspan="1" colspan="1">23&#x000b7;7&#x02013;33&#x000b7;1</td><td rowspan="1" colspan="1">28&#x000b7;4</td><td rowspan="1" colspan="1">22&#x000b7;8&#x02013;31&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;07</td><td rowspan="1" colspan="1">26&#x000b7;8</td><td rowspan="1" colspan="1">22&#x000b7;9&#x02013;28&#x000b7;8</td><td rowspan="1" colspan="1">26&#x000b7;7</td><td rowspan="1" colspan="1">22&#x000b7;0&#x02013;29&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;06</td></tr><tr><td rowspan="1" colspan="1">16 : 1</td><td rowspan="1" colspan="1">50&#x000b7;2</td><td rowspan="1" colspan="1">45&#x000b7;1&#x02013;68&#x000b7;1</td><td rowspan="1" colspan="1">49&#x000b7;4</td><td rowspan="1" colspan="1">42&#x000b7;6&#x02013;65&#x000b7;7</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">57&#x000b7;0</td><td rowspan="1" colspan="1">39&#x000b7;7&#x02013;85&#x000b7;9</td><td rowspan="1" colspan="1">69&#x000b7;6</td><td rowspan="1" colspan="1">54&#x000b7;0&#x02013;86&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">18 : 1<italic>t</italic>-6-11</td><td rowspan="1" colspan="1">7&#x000b7;9</td><td rowspan="1" colspan="1">6&#x000b7;7&#x02013;9&#x000b7;6</td><td rowspan="1" colspan="1">9&#x000b7;1</td><td rowspan="1" colspan="1">6&#x000b7;7&#x02013;9&#x000b7;9</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">9&#x000b7;9</td><td rowspan="1" colspan="1">7&#x000b7;2&#x02013;11&#x000b7;2</td><td rowspan="1" colspan="1">9&#x000b7;7</td><td rowspan="1" colspan="1">8&#x000b7;5&#x02013;12&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">18 : 1<italic>c</italic>-9</td><td rowspan="1" colspan="1">595&#x000b7;8</td><td rowspan="1" colspan="1">517&#x000b7;9&#x02013;790&#x000b7;3</td><td rowspan="1" colspan="1">594&#x000b7;5</td><td rowspan="1" colspan="1">515&#x000b7;2&#x02013;723&#x000b7;4</td><td rowspan="1" colspan="1">0&#x000b7;6</td><td rowspan="1" colspan="1">625&#x000b7;6</td><td rowspan="1" colspan="1">500&#x000b7;8&#x02013;765&#x000b7;8</td><td rowspan="1" colspan="1">776&#x000b7;8</td><td rowspan="1" colspan="1">681&#x000b7;0&#x02013;798&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;06</td><td rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td rowspan="1" colspan="1">18 : 1<italic>c</italic>-11</td><td rowspan="1" colspan="1">44&#x000b7;7</td><td rowspan="1" colspan="1">41&#x000b7;0&#x02013;52&#x000b7;7</td><td rowspan="1" colspan="1">42&#x000b7;5</td><td rowspan="1" colspan="1">41&#x000b7;0&#x02013;54&#x000b7;5</td><td rowspan="1" colspan="1">1&#x000b7;0</td><td rowspan="1" colspan="1">46&#x000b7;5</td><td rowspan="1" colspan="1">36&#x000b7;9&#x02013;57&#x000b7;1</td><td rowspan="1" colspan="1">52&#x000b7;0</td><td rowspan="1" colspan="1">45&#x000b7;0&#x02013;60&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;04</td><td rowspan="1" colspan="1">0&#x000b7;04</td></tr><tr><td rowspan="1" colspan="1">24 : 1<italic>n</italic>-9</td><td rowspan="1" colspan="1">41&#x000b7;4</td><td rowspan="1" colspan="1">34&#x000b7;9&#x02013;46&#x000b7;8</td><td rowspan="1" colspan="1">39&#x000b7;8</td><td rowspan="1" colspan="1">39&#x000b7;2&#x02013;53&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;07</td><td rowspan="1" colspan="1">38&#x000b7;0</td><td rowspan="1" colspan="1">33&#x000b7;8&#x02013;44&#x000b7;9</td><td rowspan="1" colspan="1">42&#x000b7;2</td><td rowspan="1" colspan="1">38&#x000b7;9&#x02013;46&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">18 : 3<italic>n</italic>-3</td><td rowspan="1" colspan="1">23&#x000b7;0</td><td rowspan="1" colspan="1">20&#x000b7;0&#x02013;32&#x000b7;2</td><td rowspan="1" colspan="1">48&#x000b7;6</td><td rowspan="1" colspan="1">39&#x000b7;9&#x02013;62&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;005</td><td rowspan="1" colspan="1">24&#x000b7;9</td><td rowspan="1" colspan="1">21&#x000b7;2&#x02013;28&#x000b7;3</td><td rowspan="1" colspan="1">58&#x000b7;3</td><td rowspan="1" colspan="1">49&#x000b7;5&#x02013;84&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;002</td><td rowspan="1" colspan="1">0&#x000b7;04</td></tr><tr><td rowspan="1" colspan="1">20 : 5<italic>n</italic>-3</td><td rowspan="1" colspan="1">35&#x000b7;8</td><td rowspan="1" colspan="1">24&#x000b7;4&#x02013;67&#x000b7;8</td><td rowspan="1" colspan="1">57&#x000b7;0</td><td rowspan="1" colspan="1">38&#x000b7;9&#x02013;91&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;04</td><td rowspan="1" colspan="1">28&#x000b7;0</td><td rowspan="1" colspan="1">22&#x000b7;7&#x02013;64&#x000b7;7</td><td rowspan="1" colspan="1">56&#x000b7;5</td><td rowspan="1" colspan="1">40&#x000b7;5&#x02013;76&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td rowspan="1" colspan="1">22 : 5<italic>n</italic>-3</td><td rowspan="1" colspan="1">18&#x000b7;7</td><td rowspan="1" colspan="1">17&#x000b7;0&#x02013;25&#x000b7;7</td><td rowspan="1" colspan="1">20&#x000b7;8</td><td rowspan="1" colspan="1">18&#x000b7;9&#x02013;24&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">21&#x000b7;1</td><td rowspan="1" colspan="1">18&#x000b7;5&#x02013;24&#x000b7;3</td><td rowspan="1" colspan="1">25&#x000b7;9</td><td rowspan="1" colspan="1">22&#x000b7;3&#x02013;29&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;007</td><td rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td rowspan="1" colspan="1">22 : 6<italic>n</italic>-3</td><td rowspan="1" colspan="1">106&#x000b7;3</td><td rowspan="1" colspan="1">79&#x000b7;1&#x02013;136&#x000b7;7</td><td rowspan="1" colspan="1">87&#x000b7;8</td><td rowspan="1" colspan="1">72&#x000b7;1&#x02013;110&#x000b7;7</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">90&#x000b7;1</td><td rowspan="1" colspan="1">76&#x000b7;3&#x02013;129&#x000b7;1</td><td rowspan="1" colspan="1">93&#x000b7;9</td><td rowspan="1" colspan="1">69&#x000b7;0&#x02013;129&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td rowspan="1" colspan="1">18 : 2<italic>n</italic>-6</td><td rowspan="1" colspan="1">1128&#x000b7;5</td><td rowspan="1" colspan="1">995&#x000b7;7&#x02013;1223&#x000b7;8</td><td rowspan="1" colspan="1">936&#x000b7;8</td><td rowspan="1" colspan="1">857&#x000b7;4&#x02013;1141&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">1088&#x000b7;0</td><td rowspan="1" colspan="1">1018&#x000b7;2&#x02013;1234&#x000b7;3</td><td rowspan="1" colspan="1">984&#x000b7;1</td><td rowspan="1" colspan="1">924&#x000b7;3&#x02013;1202&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;03</td><td rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td rowspan="1" colspan="1">18 : 3<italic>n</italic>-6</td><td rowspan="1" colspan="1">14&#x000b7;2</td><td rowspan="1" colspan="1">13&#x000b7;0&#x02013;18&#x000b7;4</td><td rowspan="1" colspan="1">10&#x000b7;8</td><td rowspan="1" colspan="1">8&#x000b7;3&#x02013;15&#x000b7;0</td><td rowspan="1" colspan="1">0&#x000b7;09</td><td rowspan="1" colspan="1">18&#x000b7;4</td><td rowspan="1" colspan="1">14&#x000b7;1&#x02013;21&#x000b7;1</td><td rowspan="1" colspan="1">14&#x000b7;3</td><td rowspan="1" colspan="1">9&#x000b7;8&#x02013;21&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td rowspan="1" colspan="1">20 : 2<italic>n</italic>-6</td><td rowspan="1" colspan="1">9&#x000b7;6</td><td rowspan="1" colspan="1">8&#x000b7;4&#x02013;11&#x000b7;4</td><td rowspan="1" colspan="1">8&#x000b7;6</td><td rowspan="1" colspan="1">6&#x000b7;9&#x02013;10&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">10&#x000b7;1</td><td rowspan="1" colspan="1">9&#x000b7;0&#x02013;12&#x000b7;9</td><td rowspan="1" colspan="1">10&#x000b7;9</td><td rowspan="1" colspan="1">8&#x000b7;8&#x02013;11&#x000b7;6</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;1</td></tr><tr><td rowspan="1" colspan="1">20 : 3<italic>n</italic>-6</td><td rowspan="1" colspan="1">51&#x000b7;9</td><td rowspan="1" colspan="1">37&#x000b7;7&#x02013;64&#x000b7;4</td><td rowspan="1" colspan="1">39&#x000b7;2</td><td rowspan="1" colspan="1">32&#x000b7;1&#x02013;45&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;007</td><td rowspan="1" colspan="1">53&#x000b7;3</td><td rowspan="1" colspan="1">39&#x000b7;1&#x02013;64&#x000b7;1</td><td rowspan="1" colspan="1">42&#x000b7;1</td><td rowspan="1" colspan="1">35&#x000b7;3&#x02013;56&#x000b7;8</td><td rowspan="1" colspan="1">0&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td rowspan="1" colspan="1">20 : 4<italic>n</italic>-6</td><td rowspan="1" colspan="1">210&#x000b7;7</td><td rowspan="1" colspan="1">171&#x000b7;0&#x02013;230&#x000b7;2</td><td rowspan="1" colspan="1">188&#x000b7;7</td><td rowspan="1" colspan="1">146&#x000b7;5&#x02013;209&#x000b7;2</td><td rowspan="1" colspan="1">0&#x000b7;06</td><td rowspan="1" colspan="1">201&#x000b7;9</td><td rowspan="1" colspan="1">168&#x000b7;3&#x02013;213&#x000b7;1</td><td rowspan="1" colspan="1">206&#x000b7;5</td><td rowspan="1" colspan="1">164&#x000b7;7&#x02013;217&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;05</td></tr><tr><td rowspan="1" colspan="1">22 : 4<italic>n</italic>-6</td><td rowspan="1" colspan="1">4&#x000b7;6</td><td rowspan="1" colspan="1">4&#x000b7;0&#x02013;6&#x000b7;3</td><td rowspan="1" colspan="1">4&#x000b7;3</td><td rowspan="1" colspan="1">3&#x000b7;3&#x02013;4&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;02</td><td rowspan="1" colspan="1">5&#x000b7;4</td><td rowspan="1" colspan="1">5&#x000b7;1&#x02013;6&#x000b7;7</td><td rowspan="1" colspan="1">5&#x000b7;6</td><td rowspan="1" colspan="1">4&#x000b7;4&#x02013;6&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;5</td><td rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td rowspan="1" colspan="1">22 : 5<italic>n</italic>-6</td><td rowspan="1" colspan="1">12&#x000b7;9</td><td rowspan="1" colspan="1">10&#x000b7;1&#x02013;13&#x000b7;9</td><td rowspan="1" colspan="1">12&#x000b7;1</td><td rowspan="1" colspan="1">11&#x000b7;0&#x02013;13&#x000b7;1</td><td rowspan="1" colspan="1">0&#x000b7;7</td><td rowspan="1" colspan="1">11&#x000b7;7</td><td rowspan="1" colspan="1">11&#x000b7;1&#x02013;13&#x000b7;6</td><td rowspan="1" colspan="1">11&#x000b7;8</td><td rowspan="1" colspan="1">10&#x000b7;4&#x02013;14&#x000b7;3</td><td rowspan="1" colspan="1">0&#x000b7;9</td><td rowspan="1" colspan="1">0&#x000b7;5</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>ALA, &#x003b1;-linolenic acid; DAG, diacylglycerol.</p></fn><fn><p>* Within the high-ALA-DAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02020; Within the high-ALA-TAG group (prior to Bonferroni correction).</p></fn><fn><p>&#x02021; Comparing change from baseline to the end of the study between the high-ALA-DAG
and high-ALA-TAG groups (prior to Bonferroni correction).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-9"><title>Risk of CVD (10-year risk)</title><p>A cardiovascular risk profile has been developed based on the results of the Framingham
heart study<sup>(</sup><xref rid="ref35" ref-type="bibr">
<sup>35</sup>
</xref><sup>,</sup><xref rid="ref36" ref-type="bibr">
<sup>36</sup>
</xref><sup>)</sup> for use in primary care (<uri xlink:type="simple" xlink:href="http://www.reynoldsriskscore.org/">http://www.reynoldsriskscore.org/</uri>). In addition to sex, age, systolic blood
pressure, total cholesterol, HDL-cholesterol and hsCRP, the Reynold risk score uses
information about smoking and genetic disposure (whether or not a parent had a heart
attack before the age of 60 years) to predict CVD risk. In the present study, even though
the cardiovascular risk score was relatively low, there was a mean predicted relative risk
reduction of 18&#x000b7;5&#x000a0;% (from 6&#x000b7;5 5&#x000a0;% to 5&#x000b7;3 5&#x000a0;%, <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;04) in the
high-ALA-DAG group, while the high-ALA-TAG group had a relative risk increase of 13&#x000b7;3&#x000a0;%
(from 7&#x000b7;5 3&#x000a0;% to 8&#x000b7;5 3&#x000a0;%, <italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;4) after intervention. There was a
significant difference in relative risk reduction between the two groups
(<italic>P</italic>&#x000a0;=&#x000a0;0&#x000b7;001). This significant difference remained valid even after full
Bonferroni adjustment<bold>.</bold></p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>In the present study, we found that replacing part of the TAG-containing margarine with
DAG-containing margarine (20&#x000a0;g) for 12 weeks led to an improved predicted 10 years
cardiovascular risk score in healthy, overweight subjects. This reduction in cardiovascular
risk may possibly be due to an improved metabolic phenotype appearing as reduced total body
fat percentage and reduced trunk fat mass, and increased total FFM, in addition to reduced
blood pressure. Additionally, the liver function markers ALAT, &#x003b3;-GT and ALP were also
non-significantly decreased after DAG intake.</p><p>The results are in line with other studies that showed a change in body composition after
intake of DAG with a reduction of visceral fat mass<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>,</sup><xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref><sup>,</sup><xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref><sup>)</sup> and total fat mass<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>,</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>,</sup><xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref><sup>)</sup> or total fat percentage<sup>(</sup><xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref><sup>)</sup>. The different metabolic effects after intake of DAG compared with those
after intake of TAG may be due to their structural differences and not only their fatty acid
composition since the energy value, absorptive and digestive properties are
similar<sup>(</sup><xref rid="ref39" ref-type="bibr">
<sup>39</sup>
</xref><sup>)</sup>. The main end products of lipase action on <italic>sn</italic>-1,3-DAG
are free glycerol and NEFA<sup>(</sup><xref rid="ref40" ref-type="bibr">
<sup>40</sup>
</xref><sup>)</sup>. These end-products of DAG are less readily re-synthesised into
chylomicron TAG because such a synthesis requires a glycerol-3-phosphate intermediate.
Therefore, fatty acids from DAG are likely to bypass the lymphatic system and enter the
blood via the portal vein<sup>(</sup><xref rid="ref41" ref-type="bibr">
<sup>41</sup>
</xref><sup>,</sup><xref rid="ref42" ref-type="bibr">
<sup>42</sup>
</xref><sup>)</sup> and may hence lead to increased hepatic &#x003b2;-oxidation, which have been
reported both in animal<sup>(</sup><xref rid="ref43" ref-type="bibr">
<sup>43</sup>
</xref><sup>&#x02013;</sup><xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref><sup>)</sup> and human studies<sup>(</sup><xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref><sup>,</sup><xref rid="ref48" ref-type="bibr">
<sup>48</sup>
</xref><sup>&#x02013;</sup><xref rid="ref51" ref-type="bibr">
<sup>51</sup>
</xref><sup>)</sup>.</p><p>Plasma levels of NEFA have been shown to be elevated in obese subjects<sup>(</sup><xref rid="ref52" ref-type="bibr">
<sup>52</sup>
</xref><sup>)</sup> as a consequence of increased release from the enlarged adipose tissue
and reduced clearance<sup>(</sup><xref rid="ref53" ref-type="bibr">
<sup>53</sup>
</xref><sup>)</sup>. NEFA have been shown to inhibit the anti-lipolytic action of insulin,
which again will further increase the level of NEFA and subsequently induce insulin
resistance<sup>(</sup><xref rid="ref54" ref-type="bibr">
<sup>54</sup>
</xref><sup>,</sup><xref rid="ref55" ref-type="bibr">
<sup>55</sup>
</xref><sup>)</sup>. However, the mechanisms by which obesity and NEFA cause insulin
resistance are not clearly understood; nevertheless the reduced release of NEFA into the
circulation improves insulin sensitivity<sup>(</sup><xref rid="ref56" ref-type="bibr">
<sup>56</sup>
</xref><sup>)</sup>. In the present study, we found no significant difference in the change
in NEFA between the two groups, and no correlation was found between the change in NEFA
concentration and the change in insulin resistance markers (insulin, glucose, C-peptide,
HbA1c and HOMA-IR) (data not shown).</p><p>Despite a non-significant reduction in total body fat percentage and trunk fat mass, total
body weight in the high-ALA-DAG group was not reduced; rather a non-significant increase was
observed. Inconsistent results have been described regarding the effect on body weight after
intervention with dietary DAG, with some finding a reduced body weight<sup>(</sup><xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref><sup>,</sup><xref rid="ref22" ref-type="bibr">
<sup>22</sup>
</xref><sup>)</sup> while others find no change in weigh<sup>(</sup><xref rid="ref57" ref-type="bibr">
<sup>57</sup>
</xref><sup>,</sup><xref rid="ref58" ref-type="bibr">
<sup>58</sup>
</xref><sup>)</sup>. The lack in weight reduction in the present study may be partly
explained by the finding that the amount of FFM was non-significantly increased in the
high-ALA-DAG group. The change in FFM in the high-ALA-DAG group corresponds to a 1&#x000b7;3&#x000a0;kg or
2&#x000a0;% increase in FFM, thus balancing the potential positive effect of the reduced trunk fat
mass. However, taken together, these small non-significant changes in body composition may
suggest an improvement of the metabolic phenotype in healthy, overweight individuals after
dietary DAG intervention.</p><p>Even though the total trunk fat mass was slightly reduced in the high-ALA-DAG group, hip
circumference was not changed after DAG intervention, indicating the potential effect of DAG
intake on visceral fat mass in preference to subcutaneous fat mass. Visceral fat and
subcutaneous fat are recognised to have distinct metabolic activities<sup>(</sup><xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref><sup>&#x02013;</sup><xref rid="ref9" ref-type="bibr">
<sup>9</sup>
</xref><sup>,</sup><xref rid="ref59" ref-type="bibr">
<sup>59</sup>
</xref><sup>)</sup>, in which adipokines (cytokines and hormones) are secreted in different
proportions. While cytokines are mainly secreted from visceral fat, the proportion of
secreted hormones is higher from subcutaneous fat<sup>(</sup><xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref><sup>,</sup><xref rid="ref60" ref-type="bibr">
<sup>60</sup>
</xref><sup>)</sup>. In the present study, we did not observe any change in the adipocyte
hormone concentration (leptin, resistin and adiponectin) which may be partly explained by
the lack of reduction in subcutaneous fat depots. In addition, we did not observe any
changes in levels of hsCRP in any of the groups after intervention. This is in accordance
with Nelson <italic>et al.</italic>, who did not find any change in inflammatory markers,
including CRP, after intervention with ALA in overweight, healthy
individuals<sup>(</sup><xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref><sup>,</sup><xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref><sup>,</sup><xref rid="ref61" ref-type="bibr">
<sup>61</sup>
</xref><sup>)</sup>. However, this is in contrast to what others have previously shown
regarding the anti-inflammatory effects of ALA<sup>(</sup><xref rid="ref62" ref-type="bibr">
<sup>62</sup>
</xref><sup>&#x02013;</sup><xref rid="ref64" ref-type="bibr">
<sup>64</sup>
</xref><sup>)</sup>. These studies were also different in duration, population and samples
size and thus may be explaining some of the observed discrepancy regarding CRP.</p><p>Hypertension is common in obesity<sup>(</sup><xref rid="ref65" ref-type="bibr">
<sup>65</sup>
</xref><sup>,</sup><xref rid="ref66" ref-type="bibr">
<sup>66</sup>
</xref><sup>)</sup> and a feature of the metabolic syndrome, and is also an established risk
factor for CVD<sup>(</sup><xref rid="ref67" ref-type="bibr">
<sup>67</sup>
</xref><sup>)</sup>. Systolic blood pressure was slightly reduced both within the
high-ALA-DAG group and compared with the high-ALA-TAG group. The underlying molecular
mechanisms controlling blood pressure are multi-factorial. Weight loss, and in particular
reduced visceral fat, is associated with reduced blood pressure<sup>(</sup><xref rid="ref68" ref-type="bibr">
<sup>68</sup>
</xref><sup>)</sup>. The high-ALA-DAG group non-significantly reduced the body trunk fat
mass after intervention and this small change in body fat may contribute to partly explain
the observed improvement in blood pressure in this group, although there was no association
between change in body fat and change in systolic blood pressure (data not shown).</p><p>In the present study, we did not find any significant changes in serum lipids after DAG
intake; only a non-significant reduction in total cholesterol and LDL-cholesterol was found
after 12 weeks of intervention with DAG. Others have found effects on plasma lipids after
DAG intake; however, these studies have mainly focused on postprandial measurements and/or
in groups of patients<sup>(</sup><xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref><sup>,</sup><xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref><sup>,</sup><xref rid="ref57" ref-type="bibr">
<sup>57</sup>
</xref><sup>,</sup><xref rid="ref69" ref-type="bibr">
<sup>69</sup>
</xref><sup>)</sup>.</p><p>Elevated levels of circulating ALAT and &#x003b3;-GT, without fatty liver or hepatic dysfunction,
in healthy and asymptomatic subjects may predict the future development of metabolic
diseases<sup>(</sup><xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref><sup>,</sup><xref rid="ref70" ref-type="bibr">
<sup>70</sup>
</xref><sup>&#x02013;</sup><xref rid="ref73" ref-type="bibr">
<sup>73</sup>
</xref><sup>)</sup>. Furthermore, elevated levels of ALAT and &#x003b3;-GT activities have recently
been shown to be positively associated with accumulation of visceral fat<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>)</sup>. In the present study, we found that the high-ALA-DAG group
non-significantly reduced their circulating concentrations of ALAT, &#x003b3;-GT and ALP after
intervention. Also, there was a positive association between the reduction in ALAT
concentration and the reduction in body trunk fat mass and total body fat mass. This is in
accordance with the findings of Mochizuki <italic>et al.</italic> and supports the notion
that reduction in visceral fat is favourable for improved liver function<sup>(</sup><xref rid="ref12" ref-type="bibr">
<sup>12</sup>
</xref><sup>)</sup>. The present study indicates that fatty acids taken as TAG or DAG will
affect liver function in different ways, since there was no association between ALAT and
body or trunk fat mass in the TAG group. This differential action on lipid metabolism,
explained by specific structural differences of DAG isomers, and not only the fatty acid
composition of DAG or TAG, has previously been reported<sup>(</sup><xref rid="ref74" ref-type="bibr">
<sup>74</sup>
</xref><sup>)</sup>. Murase <italic>et al.</italic> have previously shown that increased
hepatic &#x003b2;-oxidation may be the reason for reduced fatty liver formation after DAG
intake<sup>(</sup><xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref><sup>)</sup>. Fetuin-A, a marker of hepatic steatosis<sup>(</sup><xref rid="ref33" ref-type="bibr">
<sup>33</sup>
</xref><sup>)</sup>, was not changed within or between the groups after intervention.
However, fetuin-A is a marker of a more established disease (hepatic steatosis) while the
other liver function markers we measured (ASAT, ALAT, ALP and &#x003b3;-GT) reflect a more general
hepatic dysfunction. This may partly explain why fetuin-A is not changed during intervention
in the present group of healthy, overweight subjects.</p><p>The Reynold risk score is a score based on several risk factors of CVD (sex, age, blood
pressure, CRP, total cholesterol, HDL-cholesterol, smoking habits and familiar disposal).
The risk score gives a CVD prediction for the following 10 years and is intended for use in
primary care. In the present study, even though the cardiovascular risk score was relatively
low at intervention start, intervention with DAG led to a relative risk reduction of 18&#x000b7;5&#x000a0;%
and this reduction was significantly different from the TAG group, supporting the notion of
improved health after DAG intake.</p><p>The strength of the present study is the randomised controlled design and the high
compliance regarding intake of the study products. However, a major weakness in the present
study is that the number of participants was considerably reduced due to a high withdrawal
rate during the study. In a previous study investigating bioavailability of flaxseed oil, a
relatively high withdrawal rate was also observed<sup>(</sup><xref rid="ref75" ref-type="bibr">
<sup>75</sup>
</xref><sup>)</sup>. In the present study, the subjects were randomised and stratified
according to sex and age. Due to the high withdrawal rate, however, the final groups had a
skewed sex distribution. We therefore recalculated the results based on the male population
alone (<italic>n</italic> 6 and <italic>n</italic> 11 in the high-ALA-TAG and high-ALA-DAG
group, respectively), and the majority of the results still showed the same pattern. Within
the high-ALA-DAG group (Wilcoxon matched-pair signed-rank test) a reduction after
intervention was found for the following parameters: systolic blood pressure, ASAT, &#x003b3;-GT,
ALP, Reynold risk score and &#x003b1;-tocopherol/total lipids even though not all the recalculated
results (only the males) now reached statistical significance. Differences (non-significant)
between the two groups (Mann<italic>&#x02013;</italic>Whitney <italic>U</italic> test) were still
observed for ALAT, fat percentage and Reynold risk score similarly to the whole group. In
the present study, power analysis was based on the existing literature on the effect of ALA
on hsCRP, based on the assumption that changes in hsCRP would require the largest sample
size. However, in addition to hsCRP, the present study aimed to investigate several other
metabolic markers after intake of DAG oil in a Norwegian population, and may therefore be
considered exploratory. Due to the limited numbers of subjects and the multiple testing, we
performed Bonferroni correction. We cannot rule out the possibility that the results
regarding some of the other markers would have been different in a larger population.
However, body composition, another outcome in the present study, is shown by others to
significantly change with approximately ten subjects in each group<sup>(</sup><xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref><sup>,</sup><xref rid="ref76" ref-type="bibr">
<sup>76</sup>
</xref><sup>,</sup><xref rid="ref77" ref-type="bibr">
<sup>77</sup>
</xref><sup>)</sup>, which is comparable to our sample size. In order to further study
beneficial health effects of DAG, future studies should include larger sample size and
individuals with features of the metabolic syndrome which are more at risk of developing
chronic diseases such as fatty liver, CVD and type 2 diabetes mellitus.</p><p>In conclusion, the results from the present study show that replacing TAG-based food items
with DAG-based food items led to improved predicted 10 years cardiovascular risk score
together with a possible beneficial effect on body composition and blood pressure. Even
though weight was not reduced, intake of DAG-containing food items seemed to improve the
metabolic phenotype in healthy, overweight subjects with small beneficial non-significant
changes in total body fat percentage and trunk fat mass, FFM, ALAT, &#x003b3;-GT and ALP.
Altogether, this may potentially suggest beneficial health effects of DAG in healthy
overweight subjects.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The present work was performed at Oslo and Akershus University College of Applied Sciences,
Post Box 4, St. Olavsplass, 0130 Oslo, Norway. We thank our research participants for their
dedication to the project. We are also grateful to Professor Jan I. Pedersen and Professor
Lene Frost Andersen at Department of Nutrition, The Medical Faculty at the University of
Oslo for valuable discussions and critical reading of the manuscript, and Ellen Raael at
Oslo and Akershus University College of Applied Sciences for valuable assistance with this
project. We also thank Danisco AS (Brabrand, Denmark), Norsk fropresse AS (Lysaker, Norway)
and Kao Corporation (Tokyo, Japan). This study was supported by Oslo and Akershus University
College of Applied Sciences, Norway, The Throne Holst Foundation, The Nordic Center of
Excellence on Systems Biology in controlled dietary interventions and cohort studies,
SYSDIET (no. 070014), Mills DA, Oslo, Norway, and The Research Council of Norway (P.O. Box
2700, St. Hanshaugen, N-0131 Oslo, Norway). V. H. T.-H., I. N., N. W.-R., K. R., A. M., B.
H., K. B. H. and S. M. U. have no conflicts of interest, or any financial or personal
interest. L. G. is a researcher and nutrition manager, K. F. C. and A. L. are researchers in
Mills DA, Oslo, Norway. They have no financial or personal interest. V. H. T.-H., I. N., K.
R., N. W.-R., A. M., L. G., K. F. C., A. L., B. H., K. B. H. and S. M. U. designed the
research (project conception, development of overall research plan and study oversight). V.
H. T.-H., I. N., N. W.-R., K. F. C., A. L., K. B. H. and S. M. U. conducted research
(hands-on conduct of the experiments and data collection). V. H. T.-H., K. B. H. and S. M.
U. analysed the data or performed statistical analysis. V. H. T.-H., I. N., K. R., N. W.-R.,
A. M., L. G., K. F. C., A. L., B. H., K. B. H. and S. M. U. wrote the paper (the only
authors who made a major contribution). V. H. T.-H., K. B. H. and S. M. U. had primary
responsibility for the final content.</p></ack><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Rao</surname><given-names>GH</given-names></name>, <name><surname>Thethi</surname><given-names>I</given-names></name> &#x00026; <name><surname>Fareed</surname><given-names>J</given-names></name> (<year>2011</year>) <article-title>Vascular disease: obesity and excess weight as
modulators of risk</article-title>. <source>Expert Rev Cardiovasc Ther</source><volume>9</volume>, <fpage>525</fpage>&#x02013;<lpage>534</lpage><pub-id pub-id-type="pmid">21517735</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Kahn</surname><given-names>SE</given-names></name>, <name><surname>Hull</surname><given-names>RL</given-names></name> &#x00026; <name><surname>Utzschneider</surname><given-names>KM</given-names></name> (<year>2006</year>) <article-title>Mechanisms linking obesity to insulin
resistance and type 2 diabetes</article-title>. <source>Nature</source><volume>444</volume>, <fpage>840</fpage>&#x02013;<lpage>846</lpage><pub-id pub-id-type="pmid">17167471</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Kotsis</surname><given-names>V</given-names></name>, <name><surname>Stabouli</surname><given-names>S</given-names></name>, <name><surname>Papakatsika</surname><given-names>S</given-names></name>, <etal/> (<year>2010</year>) <article-title>Mechanisms of obesity-induced
hypertension</article-title>. <source>Hypertens Res</source><volume>33</volume>, <fpage>386</fpage>&#x02013;<lpage>393</lpage><pub-id pub-id-type="pmid">20442753</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Wajchenberg</surname><given-names>BL</given-names></name> (<year>2000</year>) <article-title>Subcutaneous and visceral adipose tissue: their
relation to the metabolic syndrome</article-title>. <source>Endocr Rev</source><volume>21</volume>, <fpage>697</fpage>&#x02013;<lpage>738</lpage><pub-id pub-id-type="pmid">11133069</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Perrini</surname><given-names>S</given-names></name>, <name><surname>Leonardini</surname><given-names>A</given-names></name>, <name><surname>Laviola</surname><given-names>L</given-names></name>, <etal/> (<year>2008</year>) <article-title>Biological specificity of visceral
adipose tissue and therapeutic intervention</article-title>. <source>Arch Physiol
Biochem</source><volume>114</volume>, <fpage>277</fpage>&#x02013;<lpage>286</lpage><pub-id pub-id-type="pmid">18946788</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Kershaw</surname><given-names>EE</given-names></name> &#x00026; <name><surname>Flier</surname><given-names>JS</given-names></name> (<year>2004</year>) <article-title>Adipose tissue as an endocrine
organ</article-title>. <source>J Clin Endocrinol Metab</source><volume>89</volume>, <fpage>2548</fpage>&#x02013;<lpage>2556</lpage><pub-id pub-id-type="pmid">15181022</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Galic</surname><given-names>S</given-names></name>, <name><surname>Oakhill</surname><given-names>JS</given-names></name> &#x00026; <name><surname>Steinberg</surname><given-names>GR</given-names></name> (<year>2010</year>) <article-title>Adipose tissue as an endocrine
organ</article-title>. <source>Mol Cell Endocrinol</source><volume>316</volume>, <fpage>129</fpage>&#x02013;<lpage>139</lpage><pub-id pub-id-type="pmid">19723556</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Despres</surname><given-names>JP</given-names></name> &#x00026; <name><surname>Lemieux</surname><given-names>I</given-names></name> (<year>2006</year>) <article-title>Abdominal obesity and metabolic
syndrome</article-title>. <source>Nature</source><volume>444</volume>, <fpage>881</fpage>&#x02013;<lpage>887</lpage><pub-id pub-id-type="pmid">17167477</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Nedungadi</surname><given-names>TP</given-names></name> &#x00026; <name><surname>Clegg</surname><given-names>DJ</given-names></name> (<year>2009</year>) <article-title>Sexual dimorphism in body fat distribution and
risk for cardiovascular diseases</article-title>. <source>J Cardiovasc Transl Res</source><volume>2</volume>, <fpage>321</fpage>&#x02013;<lpage>327</lpage><pub-id pub-id-type="pmid">20560019</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Kishida</surname><given-names>K</given-names></name>, <name><surname>Funahashi</surname><given-names>T</given-names></name> &#x00026; <name><surname>Shimomura</surname><given-names>I</given-names></name> (<year>2011</year>) <article-title>Clinical significance of visceral fat reduction
through health education in preventing atherosclerotic cardiovascular disease &#x02013; lesson
from the Amagasaki Visceral Fat Study: a Japanese perspective</article-title>.
<source>Nutr Metab (Lond)</source><volume>8</volume>, 57.</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>N</given-names></name>, <name><surname>Kantartzis</surname><given-names>K</given-names></name> &#x00026; <name><surname>Haring</surname><given-names>HU</given-names></name> (<year>2008</year>) <article-title>Causes and metabolic consequences of fatty
liver</article-title>. <source>Endocr Rev</source><volume>29</volume>, <fpage>939</fpage>&#x02013;<lpage>960</lpage><pub-id pub-id-type="pmid">18723451</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Mochizuki</surname><given-names>K</given-names></name>, <name><surname>Miyauchi</surname><given-names>R</given-names></name>, <name><surname>Misaki</surname><given-names>Y</given-names></name>, <etal/> (<year>2011</year>) <article-title>Accumulation of visceral fat is
positively associated with serum ALT and gamma-GTP activities in healthy and preclinical
middle-aged Japanese men</article-title>. <source>J Nutr Sci Vitaminol (Tokyo)</source><volume>57</volume>, <fpage>65</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="pmid">21512293</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Bo</surname><given-names>S</given-names></name>, <name><surname>Gambino</surname><given-names>R</given-names></name>, <name><surname>Durazzo</surname><given-names>M</given-names></name>, <etal/> (<year>2005</year>) <article-title>Associations between gamma-glutamyl
transferase, metabolic abnormalities and inflammation in healthy subjects from a
population based cohort: a possible implication for oxidative stress</article-title>.
<source>World J Gastroenterol</source><volume>11</volume>, <fpage>7109</fpage>&#x02013;<lpage>7117</lpage><pub-id pub-id-type="pmid">16437656</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Vozarova</surname><given-names>B</given-names></name>, <name><surname>Stefan</surname><given-names>N</given-names></name>, <name><surname>Lindsay</surname><given-names>RS</given-names></name>, <etal/> (<year>2002</year>) <article-title>High alanine aminotransferase is
associated with decreased hepatic insulin sensitivity and predicts the development of
type 2 diabetes</article-title>. <source>Diabetes</source><volume>51</volume>, <fpage>1889</fpage>&#x02013;<lpage>1895</lpage><pub-id pub-id-type="pmid">12031978</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Marchesini</surname><given-names>G</given-names></name>, <name><surname>Brizi</surname><given-names>M</given-names></name>, <name><surname>Bianchi</surname><given-names>G</given-names></name>, <etal/> (<year>2001</year>) <article-title>Nonalcoholic fatty liver disease: a
feature of the metabolic syndrome</article-title>. <source>Diabetes</source><volume>50</volume>, <fpage>1844</fpage>&#x02013;<lpage>1850</lpage><pub-id pub-id-type="pmid">11473047</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>van Barneveld</surname><given-names>T</given-names></name>, <name><surname>Seidell</surname><given-names>JC</given-names></name>, <name><surname>Traag</surname><given-names>N</given-names></name>, <etal/> (<year>1989</year>) <article-title>Fat distribution and gamma-glutamyl
transferase in relation to serum lipids and blood pressure in 38-year old Dutch
males</article-title>. <source>Eur J Clin Nutr</source><volume>43</volume>, <fpage>809</fpage>&#x02013;<lpage>818</lpage><pub-id pub-id-type="pmid">2576402</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Yanai</surname><given-names>H</given-names></name>, <name><surname>Tomono</surname><given-names>Y</given-names></name>, <name><surname>Ito</surname><given-names>K</given-names></name>, <etal/> (<year>2007</year>) <article-title>Diacylglycerol oil for the metabolic
syndrome</article-title>. <source>Nutr J</source><volume>6</volume>, 43.</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Taguchi</surname><given-names>H</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>, <name><surname>Onizawa</surname><given-names>K</given-names></name>, <etal/> (<year>2000</year>) <article-title>Double-blind controlled study on the
effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol
responses in healthy humans</article-title>. <source>J Am Coll Nutr</source><volume>19</volume>, <fpage>789</fpage>&#x02013;<lpage>796</lpage><pub-id pub-id-type="pmid">11194533</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Tada</surname><given-names>N</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>, <name><surname>Matsuo</surname><given-names>N</given-names></name>, <etal/> (<year>2001</year>) <article-title>Dynamics of postprandial remnant-like
lipoprotein particles in serum after loading of diacylglycerols</article-title>.
<source>Clin Chim Acta</source><volume>311</volume>, <fpage>109</fpage>&#x02013;<lpage>117</lpage><pub-id pub-id-type="pmid">11566170</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Kamphuis</surname><given-names>MM</given-names></name>, <name><surname>Mela</surname><given-names>DJ</given-names></name> &#x00026; <name><surname>Westerterp-Plantenga</surname><given-names>MS</given-names></name> (<year>2003</year>) <article-title>Diacylglycerols affect substrate oxidation and
appetite in humans</article-title>. <source>Am J Clin Nutr</source><volume>77</volume>, <fpage>1133</fpage>&#x02013;<lpage>1139</lpage><pub-id pub-id-type="pmid">12716663</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Nagao</surname><given-names>T</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>, <name><surname>Goto</surname><given-names>N</given-names></name>, <etal/> (<year>2000</year>) <article-title>Dietary diacylglycerol suppresses
accumulation of body fat compared to triacylglycerol in men in a double-blind controlled
trial</article-title>. <source>J Nutr</source><volume>130</volume>, <fpage>792</fpage>&#x02013;<lpage>797</lpage><pub-id pub-id-type="pmid">10736331</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Maki</surname><given-names>KC</given-names></name>, <name><surname>Davidson</surname><given-names>MH</given-names></name>, <name><surname>Tsushima</surname><given-names>R</given-names></name>, <etal/> (<year>2002</year>) <article-title>Consumption of diacylglycerol oil as
part of a reduced-energy diet enhances loss of body weight and fat in comparison with
consumption of a triacylglycerol control oil</article-title>. <source>Am J Clin Nutr</source><volume>76</volume>, <fpage>1230</fpage>&#x02013;<lpage>1236</lpage><pub-id pub-id-type="pmid">12450887</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <etal/> (<year>2011</year>) <article-title>&#x003b1;-Linolenic acid intake attenuates
myocardial ischemia/reperfusion injury through anti-inflammatory and anti-oxidative
stress effects in diabetic but not normal rats</article-title>. <source>Arch Med Res</source><volume>42</volume>, <fpage>171</fpage>&#x02013;<lpage>181</lpage><pub-id pub-id-type="pmid">21722811</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Rodriguez-Leyva</surname><given-names>D</given-names></name>, <name><surname>Dupasquier</surname><given-names>CM</given-names></name>, <name><surname>McCullough</surname><given-names>R</given-names></name>, <etal/> (<year>2010</year>) <article-title>The cardiovascular effects of flaxseed
and its omega-3 fatty acid, alpha-linolenic acid</article-title>. <source>Can J Cardiol</source><volume>26</volume>, <fpage>489</fpage>&#x02013;<lpage>496</lpage><pub-id pub-id-type="pmid">21076723</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Dewell</surname><given-names>A</given-names></name>, <name><surname>Marvasti</surname><given-names>FF</given-names></name>, <name><surname>Harris</surname><given-names>WS</given-names></name>, <etal/> (<year>2011</year>) <article-title>Low- and high-dose plant and marine
(<italic>n</italic>-3) fatty acids do not affect plasma inflammatory markers in adults
with metabolic syndrome</article-title>. <source>J Nutr</source><volume>141</volume>, <fpage>2166</fpage>&#x02013;<lpage>2171</lpage><pub-id pub-id-type="pmid">22031659</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>de Goede</surname><given-names>J</given-names></name>, <name><surname>Verschuren</surname><given-names>WM</given-names></name>, <name><surname>Boer</surname><given-names>JM</given-names></name>, <etal/> (<year>2011</year>) <article-title>Alpha-linolenic acid intake and 10
year incidence of coronary heart disease and stroke in 20,000 middle-aged men and women
in the Netherlands</article-title>. <source>PLoS One</source><volume>6</volume>, e17967.</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Kaul</surname><given-names>N</given-names></name>, <name><surname>Kreml</surname><given-names>R</given-names></name>, <name><surname>Austria</surname><given-names>JA</given-names></name>, <etal/> (<year>2008</year>) <article-title>A comparison of fish oil, flaxseed oil
and hempseed oil supplementation on selected parameters of cardiovascular health in
healthy volunteers</article-title>. <source>J Am Coll Nutr</source><volume>27</volume>, <fpage>51</fpage>&#x02013;<lpage>58</lpage><pub-id pub-id-type="pmid">18460481</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Barcelo-Coblijn</surname><given-names>G</given-names></name>, <name><surname>Murphy</surname><given-names>EJ</given-names></name>, <name><surname>Othman</surname><given-names>R</given-names></name>, <etal/> (<year>2008</year>) <article-title>Flaxseed oil and fish-oil capsule
consumption alters human red blood cell <italic>n</italic>-3 fatty acid composition: a
multiple-dosing trial comparing 2 sources of <italic>n</italic>-3 fatty
acid</article-title>. <source>Am J Clin Nutr</source><volume>88</volume>, <fpage>801</fpage>&#x02013;<lpage>809</lpage><pub-id pub-id-type="pmid">18779299</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Svilaas</surname><given-names>A</given-names></name>, <name><surname>Strom</surname><given-names>EC</given-names></name>, <name><surname>Svilaas</surname><given-names>T</given-names></name>, <etal/> (<year>2002</year>) <article-title>Reproducibility and validity of a
short food questionnaire for the assessment of dietary habits</article-title>.
<source>Nutr Metab Cardiovasc Dis</source><volume>12</volume>, <fpage>60</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="pmid">12189905</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Bastani</surname><given-names>NE</given-names></name>, <name><surname>Gundersen</surname><given-names>TE</given-names></name> &#x00026; <name><surname>Blomhoff</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>Determination of 8-epi PGF(2alpha)
concentrations as a biomarker of oxidative stress using triple-stage liquid
chromatography/tandem mass spectrometry</article-title>. <source>Rapid Commun Mass
Spectrom</source><volume>23</volume>, <fpage>2885</fpage>&#x02013;<lpage>2890</lpage><pub-id pub-id-type="pmid">19670343</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Panfili</surname><given-names>G</given-names></name>, <name><surname>Fratianni</surname><given-names>A</given-names></name> &#x00026; <name><surname>Irano</surname><given-names>M</given-names></name> (<year>2003</year>) <article-title>Normal phase high-performance liquid
chromatography method for the determination of tocopherols and tocotrienols in
cereals</article-title>. <source>J Agric Food Chem</source><volume>51</volume>, <fpage>3940</fpage>&#x02013;<lpage>3944</lpage><pub-id pub-id-type="pmid">12822927</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Haug</surname><given-names>IJ</given-names></name>, <name><surname>Sagmo</surname><given-names>LB</given-names></name>, <name><surname>Zeiss</surname><given-names>D</given-names></name>, <etal/> (<year>2011</year>) <article-title>Bioavailability of EPA and DHA
delivered by gelled emulsions and soft gel capsules</article-title>. <source>Eur J Lipid
Sci Technol</source><volume>113</volume>, <fpage>137</fpage>&#x02013;<lpage>145</lpage></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>N</given-names></name>, <name><surname>Hennige</surname><given-names>AM</given-names></name>, <name><surname>Staiger</surname><given-names>H</given-names></name>, <etal/> (<year>2006</year>) <article-title>Alpha2-Heremans-Schmid
glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the
liver in humans</article-title>. <source>Diabetes Care</source><volume>29</volume>, <fpage>853</fpage>&#x02013;<lpage>857</lpage><pub-id pub-id-type="pmid">16567827</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Arterburn</surname><given-names>LM</given-names></name>, <name><surname>Hall</surname><given-names>EB</given-names></name> &#x00026; <name><surname>Oken</surname><given-names>H</given-names></name> (<year>2006</year>) <article-title>Distribution, interconversion, and dose
response of <italic>n</italic>-3 fatty acids in humans</article-title>. <source>Am J
Clin Nutr</source><volume>83</volume>, <fpage>1467S</fpage>&#x02013;<lpage>1476S</lpage><pub-id pub-id-type="pmid">16841856</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Buring</surname><given-names>JE</given-names></name>, <name><surname>Rifai</surname><given-names>N</given-names></name>, <etal/> (<year>2007</year>) <article-title>Development and validation of improved
algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk
Score</article-title>. <source>JAMA</source><volume>297</volume>, <fpage>611</fpage>&#x02013;<lpage>619</lpage><pub-id pub-id-type="pmid">17299196</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Paynter</surname><given-names>NP</given-names></name>, <name><surname>Rifai</surname><given-names>N</given-names></name>, <etal/> (<year>2008</year>) <article-title>C-reactive protein and parental
history improve global cardiovascular risk prediction: the Reynolds Risk Score for
men</article-title>. <source>Circulation</source><volume>118</volume>, <fpage>2243</fpage>&#x02013;<lpage>2251</lpage><pub-id pub-id-type="pmid">18997194</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Yanagisawa</surname><given-names>Y</given-names></name>, <name><surname>Kawabata</surname><given-names>T</given-names></name>, <name><surname>Tanaka</surname><given-names>O</given-names></name>, <etal/> (<year>2003</year>) <article-title>Improvement in blood lipid levels by
dietary <italic>sn</italic>-1,3-diacylglycerol in young women with variants of lipid
transporters 54T-FABP2 and -493g-MTP</article-title>. <source>Biochem Biophys Res Commun</source><volume>302</volume>, <fpage>743</fpage>&#x02013;<lpage>750</lpage><pub-id pub-id-type="pmid">12646232</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Teramoto</surname><given-names>T</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>, <name><surname>Ito</surname><given-names>K</given-names></name>, <etal/> (<year>2004</year>) <article-title>Significant effects of diacylglycerol
on body fat and lipid metabolism in patients on hemodialysis</article-title>.
<source>Clin Nutr</source><volume>23</volume>, <fpage>1122</fpage>&#x02013;<lpage>1126</lpage><pub-id pub-id-type="pmid">15380904</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Taguchi</surname><given-names>H</given-names></name>, <name><surname>Nagao</surname><given-names>T</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>, <etal/> (<year>2001</year>) <article-title>Energy value and digestibility of
dietary oil containing mainly 1,3-diacylglycerol are similar to those of
triacylglycerol</article-title>. <source>Lipids</source><volume>36</volume>, <fpage>379</fpage>&#x02013;<lpage>382</lpage><pub-id pub-id-type="pmid">11383689</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Hara</surname><given-names>K</given-names></name>, <name><surname>Onizawa</surname><given-names>K</given-names></name>, <name><surname>Honda</surname><given-names>H</given-names></name>, <etal/> (<year>1993</year>) <article-title>Dietary diacylglycerol-dependent
reduction in serum triacylglycerol concentration in rats</article-title>. <source>Ann
Nutr Metab</source><volume>37</volume>, <fpage>185</fpage>&#x02013;<lpage>191</lpage><pub-id pub-id-type="pmid">8215235</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Tada</surname><given-names>N</given-names></name> (<year>2004</year>) <article-title>Physiological actions of diacylglycerol
outcome</article-title>. <source>Curr Opin Clin Nutr Metab Care</source><volume>7</volume>, <fpage>145</fpage>&#x02013;<lpage>149</lpage><pub-id pub-id-type="pmid">15075704</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Rudkowska</surname><given-names>I</given-names></name>, <name><surname>Roynette</surname><given-names>CE</given-names></name>, <name><surname>Demonty</surname><given-names>I</given-names></name>, <etal/> (<year>2005</year>) <article-title>Diacylglycerol: efficacy and mechanism
of action of an anti-obesity agent</article-title>. <source>Obes Res</source><volume>13</volume>, <fpage>1864</fpage>&#x02013;<lpage>1876</lpage><pub-id pub-id-type="pmid">16339116</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Murata</surname><given-names>M</given-names></name>, <name><surname>Ide</surname><given-names>T</given-names></name> &#x00026; <name><surname>Hara</surname><given-names>K</given-names></name> (<year>1997</year>) <article-title>Reciprocal responses to dietary diacylglycerol
of hepatic enzymes of fatty acid synthesis and oxidation in the rat</article-title>.
<source>Br J Nutr</source><volume>77</volume>, <fpage>107</fpage>&#x02013;<lpage>121</lpage><pub-id pub-id-type="pmid">9059234</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Murase</surname><given-names>T</given-names></name>, <name><surname>Aoki</surname><given-names>M</given-names></name>, <name><surname>Wakisaka</surname><given-names>T</given-names></name>, <etal/> (<year>2002</year>) <article-title>Anti-obesity effect of dietary
diacylglycerol in C57BL/6J mice: dietary diacylglycerol stimulates intestinal lipid
metabolism</article-title>. <source>J Lipid Res</source><volume>43</volume>, <fpage>1312</fpage>&#x02013;<lpage>1319</lpage><pub-id pub-id-type="pmid">12177175</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Murase</surname><given-names>T</given-names></name>, <name><surname>Nagasawa</surname><given-names>A</given-names></name>, <name><surname>Suzuki</surname><given-names>J</given-names></name>, <etal/> (<year>2002</year>) <article-title>Dietary alpha-linolenic acid-rich
diacylglycerols reduce body weight gain accompanying the stimulation of intestinal beta
oxidation and related gene expressions in C57BL/KsJ-db/db mice</article-title>.
<source>J Nutr</source><volume>132</volume>, <fpage>3018</fpage>&#x02013;<lpage>3022</lpage><pub-id pub-id-type="pmid">12368389</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Meng</surname><given-names>X</given-names></name>, <name><surname>Zou</surname><given-names>D</given-names></name>, <name><surname>Shi</surname><given-names>Z</given-names></name>, <etal/> (<year>2004</year>) <article-title>Dietary diacylglycerol prevents
high-fat diet-induced lipid accumulation in rat liver and abdominal adipose
tissue</article-title>. <source>Lipids</source><volume>39</volume>, <fpage>37</fpage>&#x02013;<lpage>41</lpage><pub-id pub-id-type="pmid">15055233</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Murase</surname><given-names>T</given-names></name>, <name><surname>Aoki</surname><given-names>M</given-names></name> &#x00026; <name><surname>Tokimitsu</surname><given-names>I</given-names></name> (<year>2005</year>) <article-title>Supplementation with alpha-linolenic acid-rich
diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of beta
oxidation in Zucker fatty rats</article-title>. <source>Biochim Biophys Acta</source><volume>1733</volume>, <fpage>224</fpage>&#x02013;<lpage>231</lpage><pub-id pub-id-type="pmid">15863369</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Hibi</surname><given-names>M</given-names></name>, <name><surname>Takase</surname><given-names>H</given-names></name>, <name><surname>Yasunaga</surname><given-names>K</given-names></name>, <etal/> (<year>2008</year>) <article-title>Greater fat oxidation with
diacylglycerol oil consumption for 14 days compared with triacylglycerol oil consumption
in overweight men and women</article-title>. <source>Int J Obes (Lond)</source><volume>32</volume>, <fpage>1841</fpage>&#x02013;<lpage>1847</lpage><pub-id pub-id-type="pmid">18936764</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Saito</surname><given-names>S</given-names></name>, <name><surname>Tomonobu</surname><given-names>K</given-names></name>, <name><surname>Hase</surname><given-names>T</given-names></name>, <etal/> (<year>2006</year>) <article-title>Effects of diacylglycerol on
postprandial energy expenditure and respiratory quotient in healthy
subjects</article-title>. <source>Nutrition</source><volume>22</volume>, <fpage>30</fpage>&#x02013;<lpage>35</lpage><pub-id pub-id-type="pmid">16289979</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><name><surname>Hibi</surname><given-names>M</given-names></name>, <name><surname>Takase</surname><given-names>H</given-names></name>, <name><surname>Yasunaga</surname><given-names>K</given-names></name>, <etal/> (<year>2008</year>) <article-title>Fat utilization in healthy subjects
consuming diacylglycerol oil diet: dietary and whole body fat oxidation</article-title>.
<source>Lipids</source><volume>43</volume>, <fpage>517</fpage>&#x02013;<lpage>524</lpage><pub-id pub-id-type="pmid">18408958</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><name><surname>Kimura</surname><given-names>S</given-names></name>, <name><surname>Tsuchiya</surname><given-names>H</given-names></name>, <name><surname>Inage</surname><given-names>H</given-names></name>, <etal/> (<year>2006</year>) <article-title>Effects of dietary diacylglycerol on
the energy metabolism</article-title>. <source>Int J Vitam Nutr Res</source><volume>76</volume>, <fpage>75</fpage>&#x02013;<lpage>79</lpage><pub-id pub-id-type="pmid">16941418</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><name><surname>Jensen</surname><given-names>MD</given-names></name>, <name><surname>Haymond</surname><given-names>MW</given-names></name>, <name><surname>Rizza</surname><given-names>RA</given-names></name>, <etal/> (<year>1989</year>) <article-title>Influence of body fat distribution on
free fatty acid metabolism in obesity</article-title>. <source>J Clin Invest</source><volume>83</volume>, <fpage>1168</fpage>&#x02013;<lpage>1173</lpage><pub-id pub-id-type="pmid">2649512</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><name><surname>Bjorntorp</surname><given-names>P</given-names></name>, <name><surname>Bergman</surname><given-names>H</given-names></name> &#x00026; <name><surname>Varnauskas</surname><given-names>E</given-names></name> (<year>1969</year>) <article-title>Plasma free fatty acid turnover rate in
obesity</article-title>. <source>Acta Med Scand</source><volume>185</volume>, <fpage>351</fpage>&#x02013;<lpage>356</lpage><pub-id pub-id-type="pmid">5806343</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><name><surname>Boden</surname><given-names>G</given-names></name> (<year>2011</year>) <article-title>Obesity, insulin resistance and free fatty
acids</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source><volume>18</volume>, <fpage>139</fpage>&#x02013;<lpage>143</lpage><pub-id pub-id-type="pmid">21297467</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><name><surname>Boden</surname><given-names>G</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Ruiz</surname><given-names>J</given-names></name>, <etal/> (<year>1994</year>) <article-title>Mechanisms of fatty acid-induced
inhibition of glucose uptake</article-title>. <source>J Clin Invest</source><volume>93</volume>, <fpage>2438</fpage>&#x02013;<lpage>2446</lpage><pub-id pub-id-type="pmid">8200979</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><name><surname>Santomauro</surname><given-names>AT</given-names></name>, <name><surname>Boden</surname><given-names>G</given-names></name>, <name><surname>Silva</surname><given-names>ME</given-names></name>, <etal/> (<year>1999</year>) <article-title>Overnight lowering of free fatty acids
with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and
nondiabetic subjects</article-title>. <source>Diabetes</source><volume>48</volume>, <fpage>1836</fpage>&#x02013;<lpage>1841</lpage><pub-id pub-id-type="pmid">10480616</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>K</given-names></name>, <name><surname>Asakawa</surname><given-names>H</given-names></name>, <name><surname>Tokunaga</surname><given-names>K</given-names></name>, <etal/> (<year>2001</year>) <article-title>Long-term ingestion of dietary
diacylglycerol lowers serum triacylglycerol in type II diabetic patients with
hypertriglyceridemia</article-title>. <source>J Nutr</source><volume>131</volume>, <fpage>3204</fpage>&#x02013;<lpage>3207</lpage><pub-id pub-id-type="pmid">11739866</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><name><surname>Yasunaga</surname><given-names>K</given-names></name>, <name><surname>Glinsmann</surname><given-names>WH</given-names></name>, <name><surname>Seo</surname><given-names>Y</given-names></name>, <etal/> (<year>2004</year>) <article-title>Safety aspects regarding the
consumption of high-dose dietary diacylglycerol oil in men and women in a double-blind
controlled trial in comparison with consumption of a triacylglycerol control
oil</article-title>. <source>Food Chem Toxicol</source><volume>42</volume>, <fpage>1419</fpage>&#x02013;<lpage>1429</lpage><pub-id pub-id-type="pmid">15234072</pub-id></mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="journal"><name><surname>Vohl</surname><given-names>MC</given-names></name>, <name><surname>Sladek</surname><given-names>R</given-names></name>, <name><surname>Robitaille</surname><given-names>J</given-names></name>, <etal/> (<year>2004</year>) <article-title>A survey of genes differentially
expressed in subcutaneous and visceral adipose tissue in men</article-title>.
<source>Obes Res</source><volume>12</volume>, <fpage>1217</fpage>&#x02013;<lpage>1222</lpage><pub-id pub-id-type="pmid">15340102</pub-id></mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal"><name><surname>Havel</surname><given-names>PJ</given-names></name> (<year>2004</year>) <article-title>Update on adipocyte hormones: regulation of
energy balance and carbohydrate/lipid metabolism</article-title>. <source>Diabetes</source><volume>53</volume>, <issue>Suppl. 1</issue>,
<fpage>S143</fpage>&#x02013;<lpage>S151</lpage><pub-id pub-id-type="pmid">14749280</pub-id></mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>TL</given-names></name>, <name><surname>Stevens</surname><given-names>JR</given-names></name> &#x00026; <name><surname>Hickey</surname><given-names>MS</given-names></name> (<year>2007</year>) <article-title>Inflammatory markers are not altered by an
eight week dietary alpha-linolenic acid intervention in healthy abdominally obese adult
males and females</article-title>. <source>Cytokine</source><volume>38</volume>, <fpage>101</fpage>&#x02013;<lpage>106</lpage><pub-id pub-id-type="pmid">17613244</pub-id></mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal"><name><surname>Rallidis</surname><given-names>LS</given-names></name>, <name><surname>Paschos</surname><given-names>G</given-names></name>, <name><surname>Liakos</surname><given-names>GK</given-names></name>, <etal/> (<year>2003</year>) <article-title>Dietary alpha-linolenic acid decreases
C reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic
patients</article-title>. <source>Atherosclerosis</source><volume>167</volume>, <fpage>237</fpage>&#x02013;<lpage>242</lpage><pub-id pub-id-type="pmid">12818406</pub-id></mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>G</given-names></name>, <name><surname>Etherton</surname><given-names>TD</given-names></name>, <name><surname>Martin</surname><given-names>KR</given-names></name>, <etal/> (<year>2004</year>) <article-title>Dietary alpha-linolenic acid reduces
inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and
women</article-title>. <source>J Nutr</source><volume>134</volume>, <fpage>2991</fpage>&#x02013;<lpage>2997</lpage><pub-id pub-id-type="pmid">15514264</pub-id></mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal"><name><surname>Bemelmans</surname><given-names>WJ</given-names></name>, <name><surname>Lefrandt</surname><given-names>JD</given-names></name>, <name><surname>Feskens</surname><given-names>EJ</given-names></name>, <etal/> (<year>2004</year>) <article-title>Increased alpha-linolenic acid intake
lowers C-reactive protein, but has no effect on markers of
atherosclerosis</article-title>. <source>Eur J Clin Nutr</source><volume>58</volume>, <fpage>1083</fpage>&#x02013;<lpage>1089</lpage><pub-id pub-id-type="pmid">15220952</pub-id></mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal"><name><surname>Kotsis</surname><given-names>V</given-names></name>, <name><surname>Stabouli</surname><given-names>S</given-names></name>, <name><surname>Bouldin</surname><given-names>M</given-names></name>, <etal/> (<year>2005</year>) <article-title>Impact of obesity on 24-hour
ambulatory blood pressure and hypertension</article-title>. <source>Hypertension</source><volume>45</volume>, <fpage>602</fpage>&#x02013;<lpage>607</lpage><pub-id pub-id-type="pmid">15723966</pub-id></mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><name><surname>Stabouli</surname><given-names>S</given-names></name>, <name><surname>Kotsis</surname><given-names>V</given-names></name>, <name><surname>Papamichael</surname><given-names>C</given-names></name>, <etal/> (<year>2005</year>) <article-title>Adolescent obesity is associated with
high ambulatory blood pressure and increased carotid intimal-medial
thickness</article-title>. <source>J Pediatr</source><volume>147</volume>, <fpage>651</fpage>&#x02013;<lpage>656</lpage><pub-id pub-id-type="pmid">16291358</pub-id></mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal"><name><surname>Stamler</surname><given-names>J</given-names></name>, <name><surname>Stamler</surname><given-names>R</given-names></name> &#x00026; <name><surname>Neaton</surname><given-names>JD</given-names></name> (<year>1993</year>) <article-title>Blood pressure, systolic and diastolic, and
cardiovascular risks. US population data</article-title>. <source>Arch Intern Med</source><volume>153</volume>, <fpage>598</fpage>&#x02013;<lpage>615</lpage><pub-id pub-id-type="pmid">8439223</pub-id></mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal"><name><surname>MacMahon</surname><given-names>S</given-names></name>, <name><surname>Cutler</surname><given-names>J</given-names></name>, <name><surname>Brittain</surname><given-names>E</given-names></name>, <etal/> (<year>1987</year>) <article-title>Obesity and hypertension:
epidemiological and clinical issues</article-title>. <source>Eur Heart J</source><volume>8</volume>, <issue>Suppl. B</issue>,
<fpage>57</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="pmid">3301356</pub-id></mixed-citation></ref><ref id="ref69"><label>69.</label><mixed-citation publication-type="journal"><name><surname>Meguro</surname><given-names>S</given-names></name>, <name><surname>Higashi</surname><given-names>K</given-names></name>, <name><surname>Hase</surname><given-names>T</given-names></name>, <etal/> (<year>2001</year>) <article-title>Solubilization of phytosterols in
diacylglycerol versus triacylglycerol improves the serum cholesterol-lowering
effect</article-title>. <source>Eur J Clin Nutr</source><volume>55</volume>, <fpage>513</fpage>&#x02013;<lpage>517</lpage><pub-id pub-id-type="pmid">11464223</pub-id></mixed-citation></ref><ref id="ref70"><label>70.</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>CH</given-names></name>, <name><surname>Park</surname><given-names>JY</given-names></name>, <name><surname>Lee</surname><given-names>KU</given-names></name>, <etal/> (<year>2009</year>) <article-title>Association of serum
gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2
diabetes mellitus independent of fatty liver</article-title>. <source>Diabetes Metab Res
Rev</source><volume>25</volume>, <fpage>64</fpage>&#x02013;<lpage>69</lpage><pub-id pub-id-type="pmid">19065605</pub-id></mixed-citation></ref><ref id="ref71"><label>71.</label><mixed-citation publication-type="journal"><name><surname>Ford</surname><given-names>ES</given-names></name>, <name><surname>Schulze</surname><given-names>MB</given-names></name>, <name><surname>Bergmann</surname><given-names>MM</given-names></name>, <etal/> (<year>2008</year>) <article-title>Liver enzymes and incident diabetes:
findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)
Potsdam Study</article-title>. <source>Diabetes Care</source><volume>31</volume>, <fpage>1138</fpage>&#x02013;<lpage>1143</lpage><pub-id pub-id-type="pmid">18346992</pub-id></mixed-citation></ref><ref id="ref72"><label>72.</label><mixed-citation publication-type="journal"><name><surname>Doi</surname><given-names>Y</given-names></name>, <name><surname>Kubo</surname><given-names>M</given-names></name>, <name><surname>Yonemoto</surname><given-names>K</given-names></name>, <etal/> (<year>2007</year>) <article-title>Liver enzymes as a predictor for
incident diabetes in a Japanese population: the Hisayama study</article-title>.
<source>Obesity (Silver Spring)</source><volume>15</volume>, <fpage>1841</fpage>&#x02013;<lpage>1850</lpage><pub-id pub-id-type="pmid">17636103</pub-id></mixed-citation></ref><ref id="ref73"><label>73.</label><mixed-citation publication-type="journal"><name><surname>Wannamethee</surname><given-names>SG</given-names></name>, <name><surname>Shaper</surname><given-names>AG</given-names></name>, <name><surname>Lennon</surname><given-names>L</given-names></name>, <etal/> (<year>2005</year>) <article-title>Hepatic enzymes, the metabolic
syndrome, and the risk of type 2 diabetes in older men</article-title>. <source>Diabetes
Care</source><volume>28</volume>, <fpage>2913</fpage>&#x02013;<lpage>2918</lpage><pub-id pub-id-type="pmid">16306554</pub-id></mixed-citation></ref><ref id="ref74"><label>74.</label><mixed-citation publication-type="journal"><name><surname>Murase</surname><given-names>T</given-names></name>, <name><surname>Mizuno</surname><given-names>T</given-names></name>, <name><surname>Omachi</surname><given-names>T</given-names></name>, <etal/> (<year>2001</year>) <article-title>Dietary diacylglycerol suppresses high
fat and high sucrose diet-induced body fat accumulation in C57BL/6J
mice</article-title>. <source>J Lipid Res</source><volume>42</volume>, <fpage>372</fpage>&#x02013;<lpage>378</lpage><pub-id pub-id-type="pmid">11254749</pub-id></mixed-citation></ref><ref id="ref75"><label>75.</label><mixed-citation publication-type="journal"><name><surname>Austria</surname><given-names>JA</given-names></name>, <name><surname>Richard</surname><given-names>MN</given-names></name>, <name><surname>Chahine</surname><given-names>MN</given-names></name>, <etal/> (<year>2008</year>) <article-title>Bioavailability of alpha-linolenic
acid in subjects after ingestion of three different forms of flaxseed</article-title>.
<source>J Am Coll Nutr</source><volume>27</volume>, <fpage>214</fpage>&#x02013;<lpage>221</lpage><pub-id pub-id-type="pmid">18689552</pub-id></mixed-citation></ref><ref id="ref76"><label>76.</label><mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>K</given-names></name>, <name><surname>Tomonobu</surname><given-names>K</given-names></name>, <name><surname>Asakawa</surname><given-names>H</given-names></name>, <etal/> (<year>2006</year>) <article-title>Diet therapy with diacylglycerol oil
delays the progression of renal failure in type 2 diabetic patients with
nephropathy</article-title>. <source>Diabetes Care</source><volume>29</volume>, <fpage>417</fpage>&#x02013;<lpage>419</lpage><pub-id pub-id-type="pmid">16443898</pub-id></mixed-citation></ref><ref id="ref77"><label>77.</label><mixed-citation publication-type="journal"><name><surname>Matsuyama</surname><given-names>T</given-names></name>, <name><surname>Shoji</surname><given-names>K</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>, <etal/> (<year>2006</year>) <article-title>Effects of diacylglycerol oil on
adiposity in obese children: initial communication</article-title>. <source>J Pediatr
Endocrinol Metab</source><volume>19</volume>, <fpage>795</fpage>&#x02013;<lpage>804</lpage><pub-id pub-id-type="pmid">16886587</pub-id></mixed-citation></ref></ref-list></back></article>